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Most breast cancers occur sporadically due to long-term exposure to low-dose 
carcinogens present in our environment and diet. American lifestyles involve frequent exposures 
to smoke, polluted air, and high temperature-cooked meats comprising multiple carcinogens, 
such as 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), benzo[α[alpha]]pyrene 
(B[α[alpha]]P), and  2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP).  To investigate 
whether these carcinogens may act together to enhance breast cell carcinogenesis, we used our 
chronically-induced breast cell carcinogenesis model wherein we repeatedly expose non-
cancerous human breast epithelial MCF10A cells to physiologically-achievable doses of 
carcinogens to progressively induce cellular acquisition of cancer-associated properties including 
reduced dependence on growth factors, anchorage-independent growth, increased cell 
proliferation, migration and invasion and enriched stem-like cell population. These properties are 
then used as targets to identify dietary agents capable of blocking carcinogen-induced breast cell 
carcinogenesis.  
In the first part of this research (Chapter 2), we demonstrated that cumulative exposures 
to combined NNK and B[α[alpha]]P (NB) holistically enhanced progression of breast cell 
carcinogenesis chronically-induced by PhIP. Cells co-exposed to NB and PhIP (NBP) acquired 
higher degrees of cancer-associated properties including enhanced induction of the epithelial-to-
mesenchymal transition program and enriched stem-like cell populations compared to cells 
sequentially exposed to NB followed by PhIP (NB/P). Using these cancer-associated properties 
as targets, we demonstrated that combined green tea catechins (GTCs) were more effective than 
individual catechins in suppression of cellular carcinogenesis chronically induced by NBP.   
vi 
 
Studies in Chapter 3 revealed that reactive oxygen species (ROS) and ERK pathway 
activation were transiently induced by NBP during each exposure. Cross-talk between reinforced 
ROS elevation and the ERK pathway played an essential role in increased DNA oxidation and 
damage which contributed to enhanced initiation of cellular carcinogenesis and led to enhanced 
acquisition of cancer-associated properties. Using NBP-induced transient changes and cancer-
associated properties as targets, we revealed that physiologically-achievable levels of combined 
dietary ergosterol and mimosine were highly effective in blocking NBP-induced transient 
endpoints, including ROS-mediated DNA oxidation, which accounted for their ability to 
suppress progression of NBP-induced cellular carcinogenesis. Thus, combined dietary 
components such as GTCs, ergosterol and mimosine should be considered for affordable 
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 Given the ubiquitous nature of tobacco smoke, carbon exhaust, and cooked meat in 
modern societies, it is important to holistically examine the role of carcinogens, such as NNK, 
B[α]P, and PhIP, in induction of breast cell carcinogenesis to reveal associated mechanisms and 
targeted endpoints for intervention. The objectives of this study were to (1) elucidate the ability, 
and associated mechanisms, of environmental carcinogens NNK and B[α]P to enhance breast 
cell carcinogenesis induced by dietary carcinogen PhIP and (2) demonstrate the ability, and 
associated mechanisms, of combined dietary agents to more effectively suppress breast cell 
carcinogenesis induced by combined NNK, B[α]P, and PhIP.   
 
Breast Cancer 
 Cancer refers to a group of diseases characterized by abnormal and uncontrollable cell 
growth which ultimately leads to the formation of a mass or tumor. Breast cancer can begin in 
the breast tissue, which consists of fatty, connective and lymphatic tissues, the glands for milk 
production, called lobules, or the ducts that connect these lobules to the nipple [1]. Cancers that 
originate in the duct are known as ductal carcinomas while those originating in the lobules are 
called lobular carcinomas [2]. Breast cancer is the most common type of cancer and second-
leading cause of cancer related death among women in North America and Europe [1,2]. The 
National Cancer Institute projects there will be 232,670 new cases of invasive breast cancer in 
American women in 2014 resulting in approximately 40,000 deaths [2]. On a global scale, breast 
cancer represents 23% of all cancers diagnosed in women [3]. While rates of breast cancer vary 
3 
 
around the world, developed countries typically have rates that are much higher than developing 
countries [4] (Figure 1.1). 
 
Stages of Breast Cancer 
 Staging is the process of assessing how advanced a cancer has progressed and where it is 
located in the body. The purpose of staging is to ascertain the extent and severity of the disease 
in an individual [5]. Staging of breast cancer is important for determining prognosis and 
treatment options. As described by the National Cancer Institute [6], the four stages of breast 
cancer are as follows (Figure 1.2): 
Stage 0: (carcinoma in situ) 
This is a pre-cancerous stage of which three types exist: 
a) Ductal carcinoma in situ (DCIS): a non-invasive condition in which abnormal cells 
are found in the lining of a breast duct. These cells have not spread outside of the duct 
to other tissues of the breast.  
b) Lobular carcinoma in situ (LCIS): a non-invasive condition in which abnormal cells 
are found in the lobules of the breast. These cells have not spread outside of the 
lobule to other tissues of the breast; however, having LCIS increases the risk of 
developing invasive breast cancer. 
Stage I:  
During Stage I, cancer has formed in either breast. Stage one tumors are typically 2 centimeters 
or less in diameter and have not spread outside of the breast tissue. 




Stage II describes invasive breast cancer in which one of the following is true: 
a) The tumor is 2 centimeters or less in diameter, but has spread to the lymph nodes 
under the arm. 
b) The tumor is 2-5 centimeters in diameter and may or may not have spread to the 
lymph nodes under the arm.  
c) No tumor is found in the breast, but breast cancer cells are found in the lymph nodes 
under the arm. 
d) The tumor is more than 5 centimeters in diameter, but hasn’t spread to any lymph 
nodes.  
Stage III: 
Stage III cancers are invasive but have not yet spread to distant sites. This stage is further divided 
into three substages: 
a) Stage IIIA: Breast tumor is more than 5 centimeters in diameter and has spread to one 
to three lymph nodes under the arm; or tumor can be any size and has spread to 
multiple lymph nodes under the arm. 
b) Stage IIIB: A tumor of any size that has spread to skin or muscle tissues near the 
breast and may have spread to lymph nodes under the arm or within the breast itself. 
c) Stage IIIC: A tumor of any size that has spread to 10 or more lymph nodes under the 







Stage IV cancers are metastatic and have spread beyond the breast and the adjacent lymph nodes 
to distant organs of the body such as the lungs, liver, bone or brain.  
 
Classification of Breast Cancer 
 Breast cancer is a group of diseases which encompasses various subtypes defined by 
distinct morphological characteristics and clinical outcomes. According to the World Health 
Organization, the most common type of breast cancer is invasive ductal carcinoma (IDC) [7]. 
IDC, which represents 8 out of 10 invasive breast cancers, starts in the milk duct and then 
spreads into the fatty tissue of the breast [7]. From here, it may metastatize to other organs of the 
body through the bloodstream or lymphatic system. The next most common type of breast cancer 
is invasive lobular carcinoma (ILC) which arises from the milk-producing gland and also can 
metastasize throughout the body [7].  
Newer technologies such as immunohistochemistry, cytogenetics and cDNA microarray 
analysis have been employed to further classify invasive breast cancers into four distinct 
molecular subtypes based on genetic factors, hormone receptor status and HER2/neu status [8]. 
As seen in Figure 1.3, these subtypes are named Luminal A, Luminal B, Triple negative/basal-
like, and HER2 type [8]: 
a) Luminal A: Luminal tumors occur in the inner lining of the mammary duct and 
account for most breast cancers. Luminal A tumor cells are estrogen receptor-positive 
(ER
+
) and/or progesterone receptor-positive (PR
+
) and human epidermal growth 
factor receptor-negative (HER2/neu
-
). These tumors are typically low-grade (grade 1 
or 2) and are slow-growing and well-differentiated. Mutations in the tumor suppressor 
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gene p53, which are correlated with poor prognosis, occur in less than 15% of luminal 
A tumors. These tumors have the best prognosis of all four subtypes of breast cancer 
with high survival and low recurrence rates.  
b) Luminal B: These tumors also occur in the inner lining of the mammary duct. 






 and/or highly positive for 
Ki67, a marker for tumor cell proliferation. Compared to luminal A tumors, luminal B 
tumors have a poorer prognosis due to higher grade tumors (grade 3) which are 
larger, fast-growing and poorly-differentiated, invasion of cancer cells into the lymph 
nodes, and p53 mutations in about 30% of all tumors. Luminal B tumors are also 
more commonly diagnosed in women at a younger age. However, women with 
luminal B tumors still have considerably high survival rates, although not as high as 
women with luminal A tumors.  
c) Triple negative/basal-like: Triple negative tumor cells are ER-, PR-, and HER2/neu-. 
Most triple negative tumors are classified as basal-like because the tumor cells 
resemble cells of the outer (basal) lining of the mammary duct. Triple negative 
tumors account for 15-20% of all breast cancers and are often aggressive, fast 
growing and have poor prognosis. Most contain p53 mutations and mutations in the 
BRCA1 gene. Since triple negative tumors do not express any hormone receptors, 
they do not respond to traditional hormone-based chemotherapies and are therefore 
more difficult to treat. Triple negative breast cancer is more common in younger 
women and women of African-American decent and is more likely to recur than any 
other subtype of breast cancer.  
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. They account for 10-15% of all breast cancers and have a fairly poor 
prognosis due to high grade tumors, invasion of cancer cells into the lymph nodes, 
and p53 mutations in about 75% of all tumors. They recur often, have a tendency to 
metastasize early, and occur more commonly in younger women than luminal A or B 
tumors.     
 
Risk Factors for Breast Cancer 
 A risk factor is any environmental or genetic factor that increases a person’s chance of 
getting a disease. Since cancer represents a diverse group of diseases, different cancers therefore 
have different risk factors. Figure 1.4 summarizes the known risk factors for breast cancer as 
stated by the Breast Cancer Organization [9]. Being a woman is the biggest risk factor for 
developing breast cancer as men account for less than 1% of all new breast cancer cases. After 
gender, age is the most significant risk factor with about two-thirds of invasive breast cancers 
occurring in women 55 or older. Family history also contributes to breast cancer risk. Women 
that have a first-degree relative (mother, daughter, sister) that has been diagnosed with breast 
cancer have double the average risk of developing the disease.  
Approximately 5-10% of breast cancers are thought to be hereditary [9]. Most cases of 
hereditary breast cancer are associated with mutations in the BRCA1/2 tumor suppressor genes 
[9, 10]. The BRCA1/2 proteins form a complex that participates in a DNA damage response 
pathway that initiates homologous recombination and double-strand break repairs [11]. Loss of 
functional BRCA1/2 results in an inability to repair DNA leading to mutations in other genes. As 
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a result, women who have inherited inactivating mutations in either the BRCA1 or BRCA2 genes 
have a significantly increased risk of developing breast and/or ovarian cancer [10]. 
 One’s personal history of breast or other cancers can influence the risk of developing new 
breast cancer. If you’ve previously had breast cancer, you are 3-4 times more likely to develop 
new cancer in a different part of the breast and this risk is in addition to the risk of the original 
cancer coming back (recurrence) [9]. Even being diagnosed with certain benign breast conditions 
can increase the risk of breast cancer development. Also, radiation exposure to the chest or face 
to treat another type of cancer can increase the risk for developing breast cancer later in life [9].    
 Other biological factors known to be associated with increased risk of breast cancer are 
early first menses (age 12 or younger), late occurring menopause (after age 55), and not having 
had a full-term pregnancy by age 30 [9]. Race and ethnicity also play a role in assessing breast 
cancer susceptibility. While Caucasian women are slightly more likely to develop breast cancer 
than African-American, Hispanic or Asian women, African-American women are more likely to 
develop aggressive, early-onset, and advanced-stage breast cancer [9].  
 Overweight and obese women are at a higher risk for developing breast cancer than 
women who maintain a normal weight, especially after menopause [9]. Being overweight can 
also increase the risk of recurrence in women who have already had the disease. Other lifestyle 
factors that contribute to increased risk of breast cancer include lack of exercise, smoking, 
alcohol consumption and using hormone replacement therapy after menopause [9].  
 Studies have shown that only 5-10% of breast cancers have a genetic basis [12]. Most 
breast cancers are non-genetic and are caused by environmental factors. Subsequently, it is 





 Carcinogens are any naturally-occurring or synthetic substance that can cause cancer. 
Humans are exposed to a variety of chemicals from the environment each day. Chemicals in air, 
water, soil and food as well as occupational exposure and lifestyle factors all contribute to the 
complex exposure situation most people experience in their daily lives [13]. Approximately 90% 
of breast cancers are considered non-hereditary or ‘sporadic’ [12]. These sporadically occurring 
cancers often result from chronic exposure of human tissues to low-doses of environmental 
carcinogens. Thus, it is imperative to study and understand the factors that contribute to sporadic 
breast cancers in order to devise an effective strategy for preventing and controlling these 
diseases. Figure 1.5 shows the types of environmental factors that have the potential to cause 
non-hereditary cancer. The American Cancer Society [14] has classified these factors as related 
to lifestyle (tobacco, alcohol, diet, inactivity, being overweight), naturally-occurring substances 
(ultraviolet radiation, infectious agents, radon), chemicals in the home or workplace (auto 
exhaust, second-hand smoke, asbestos), medical treatments (hormone-replacement therapy, 
immune-suppressing treatments) and others.  
 
Related to Lifestyle 
 Factors related to lifestyle are often not cancer-causing agents themselves, but are risk 
factors associated with the genesis of cancer since they ultimately result in exposure to higher 
levels of carcinogens [15]. It is well recognized that tobacco use, alcohol consumption, diet 





 Tobacco smoking is a significant risk factor for the initiation and progression of human 
carcinogenesis in multiple organs [16]. Tobacco smoke contains thousands of carcinogenic 
compounds including mutagens such as polycyclic aromatic hydrocarbons and nitrosamines [16]. 
Smoking is a risk factor for many types of cancer, most notably lung cancer, but also cancers of 
the digestive tract, bladder, liver, esophagus, kidney, stomach, pancreas, breast and cervix [17]. 
The link between smoking and breast cancer is controversial; however, recent studies indicate that 
exposure to tobacco smoke can increase breast cancer risk, especially in post-menopausal women [18-20]. 
Since many of these cancers are associated with poor prognosis, tobacco use is by far the most 
widespread link between exposure to carcinogens and cancer-related death [16]. 
 
Alcohol Consumption 
 Alcohol is not by itself mutagenic to DNA and therefore is not a true carcinogen. Rather, 
alcohol acts mainly as a co-carcinogen by influencing the metabolic activation of other 
carcinogens [16]. Epidemiological data supports the classification of alcohol as a human 
carcinogen [21] and other studies have shown that alcohol can potentiate the carcinogenic 
potential associated with other risk factors such as smoking [22]. 
 
Diet 
  Several studies have indicated an association between a diet rich in calories and fat and 
low in fiber and the development of several cancers (prostate, breast and colon) in developed 
countries [23,24]. A major class of dietary carcinogens is heterocyclic amines which are present 
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in high quantities in well-done meats [25].  These compounds are highly mutagenic and 
epidemiological studies have indicated that consumption of well-done meat may play a role in 
the development of breast and other cancers [26]. 
 
Obesity and Sedentary Lifestyle 
 Obesity and inactivity are touted as important risk factors contributing to the 
development of a myriad of diseases, including many cancers [27]. Obesity was also shown to 
increase cancer-related mortality in a cohort of US adults [28]. Rates of breast and other cancers 
are higher in developed countries where a substantial portion of the population is obese or 
overweight due to poor diet and physical inactivity [29]. According to the American Institute for 
Cancer Research, body fat alone is responsible for over 100,000 cancers in the US annually 





 Ultraviolet Rays 
 Ultraviolet rays and ionizing radiation have the potential to cause DNA damage and 
contribute to cancer development, particularly melanoma [31]. In fact, UV irradiation is one of 
the most relevant risk factors for the development of skin cancer [32]. UV radiation is considered 
a complete carcinogen since it is mutagenic and acts as both a tumor initiator and tumor 
promoter [32]. Partially due to increased recreational sunbathing and use of tanning beds, UV-
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induced tumors are rapidly rising in incidence not only in the US but also in Europe and 
Australia [33]. 
 
 Infectious Agents 
 Studies have indicated that 18-20% of cancers are linked to infectious agents such as 
viruses, bacteria and parasites [34]. Some infectious agents cause inflammation which may 
enhance tumorigenicity [34] and retroviruses can cause incorporation or disruption of proto-
oncogenes [35]. The bacterium H. pylori has been shown to have a causal relationship to gastric 
cancer [36] and human papilloma virus (HPV) has been linked to cervical cancer [37]. New 
studies are consistently detecting numerous emerging pathogens capable of causing cancer in 
humans [38].  
 
Radon 
 Radon, a colorless, odorless, radioactive gas, is produced from the radioactive decay of 
uranium or thorium and is among the most widely studied environmental carcinogens [39]. It is 
found in soil, rock and water and can even get into indoor and outdoor air [40]. Levels are 
especially high in basements where radon leaks in through gaps in the floor or walls [40]. 
Exposure to high levels of radon has been linked to lung cancer and is the second leading cause 
of lung cancer incidence after smoking [39]. In the US alone, radon is responsible for 





Chemicals in the Home or Workplace 
A large number of chemical carcinogens are recognized by the National Institute of 
Environmental Health Sciences as “known” or “reasonably anticipated” to cause cancer. The list 
includes benzene, diesel exhaust, tobacco smoke, pesticides, substances used for some industrial 
processes such as cadmium used to manufacture batteries and compounds found in some 
consumer goods such as diethanolamine (DEA) which is present in many shampoos and lotions 
[41]. Many other environmental substances are currently under investigation to determine their 
carcinogenic potential. Some important chemical carcinogens are discussed in detail below. 
 
Diesel Exhaust 
Diesel exhaust is produced from the combustion of diesel fuel given off by vehicles that 
run on diesel engines such as cars, trucks, farm equipment and construction vehicles [42]. It is a 
major component of air pollution as it contains many toxic contaminants such as sulfur oxides 
and particulate matter [42] and is classified as an environmental carcinogen [41]. Exposure to 
diesel exhaust is associated with increased risk of lung cancer with those experiencing high 
occupational exposure being the most susceptible [43].  
 
Second-hand Smoke 
Also referred to as passive smoke, second-hand smoke contains over 4,000 chemical 
compounds, over 60 of which are either known or suspected to cause human cancer [44]. 
Second-hand smoke is especially unhealthy in enclosed areas such as homes, cars, offices and 
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restaurants. Exposure to second-hand smoke has been shown to be linked with increased 
incidence of lung cancer [45] and breast cancer, especially in post-menopausal women [18-20].  
 
 Asbestos 
 Asbestos is a commercial term used to refer to a group of naturally-occurring fibrous 
silicate minerals once widely used in the construction industry to insulate homes and buildings 
[46]. Still found in older buildings, exposure to asbestos is known to increase the risk of lung and 
laryngeal cancers, malignant mesothelioma (a rare cancer of the outer protective lining of the 
lung and inner chest cavity) as well as non-cancerous respiratory diseases such as asbestosis, 
especially in those who experience high occupational exposure [47]. The total number of deaths 
in the US due to asbestos-related lung cancer, mesothelioma and asbestosis resulting from 
workplace exposure is estimated to be over 200,000 in 2014 [48]. 
 
Medical Treatments 
 Hormone replacement therapy (HRT) is used extensively to treat osteoporosis and relieve 
symptoms of menopause. However, its widespread long-term use for prevention of 
cardiovascular disease or cognitive decline has been disputed by several epidemiological studies 
that have linked such therapies to a variety of cancers [49-53]. The risk of breast cancer varies 
with the type of HRT. The most significant risk is associated with opposed estrogen (combined 
estrogen and progesterone) given in oral form, which further increases breast cancer risk the 
longer it is used [50]. HRT has also been shown to increase the risk of ovarian [51], colorectal 
[52] and brain cancers [53].  
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 Immunosuppressive medications are necessary to prevent graft or organ rejection in 
patients who have recently received transplants. As a result of suppressing the immune system, 
organ transplant recipients are at an increased risk for developing infections and certain types of 
cancers [54-55]. The mechanisms by which immunosuppressive medications promote tumor 
growth is not currently known, however several studies have associated the type, duration and 
intensity of immunosuppressive treatments with the development of skin cancer [56] and 
lymphoma [57].  
 
Others 
 There are many other environmental factors that play a role in cancer development. Air-
borne particulate materials from vehicles and industrial processes that cause cancer include 
powdered cobalt and nickel and crystalline silica [58]. Other carcinogens we encounter in our 
everyday lives include antiperspirants, talcum powder, hair dyes and some cosmetics [59], but 
exposure to these chemicals needs to be at occupational levels to cause a significant carcinogenic 
effect [60].  
 This study concerns the activity of the environmental carcinogens 4-(methylnitros-
amino)-1-(3-pyridyl)-1-butanone (NNK) and benzo[α]pyrene (B[α]P) and the dietary carcinogen 
2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP) to induce and enhance breast cell 





 The role of tobacco carcinogens in the development of human breast cancer is still up for 
debate, however increasing evidence suggests a link between active and passive smoking and 
high incidence of sporadic breast cancer, especially in post-menopausal women [16, 18-20, 61-
64]. Therefore, it is important to investigate the impact of long-term cumulative exposure to 
tobacco carcinogens on chronic transformation of breast epithelial cells in order to elucidate the 
roles of these carcinogens in the progressive development of breast cancer.  
 Nicotine-derived nitrosamine ketone (NNK), or 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone (Figure 1.6A), is a tobacco-specific nitrosamine produced from the nitrosation of 
nicotine that occurs during the curing and processing of tobacco [65]. NNK is a pro-carcinogen 
that requires metabolic activation by the cytochrome P450 enzyme CYP2A6 [66]. NNK is 
considered one of the most potent carcinogens in tobacco products and is known to induce a high 
incidence of lung cancers in humans [67-68] and laboratory animals [69-70]. Active metabolites 
of NNK frequently form DNA adducts which result in activating point mutations of proto-
oncogenes [71, 72]. NNK also acts as a potent agonist for β-adrenergic and α7-nicotinic 
acetylcholine receptors and stimulates arachidonic acid-dependent and ERK-dependent 
mitogenic pathways associated with these receptors [73-76].  
 The association between smoking and breast cancer is still controversial. Some studies 
have indicated that smoking has no influence on breast cancer incidence [77] while others have 
shown a correlation between the two [78]. Recent cohort studies in Canada [18] and the United 
States [20] have determined that active smoking and exposure to second-hand smoke increases 
breast cancer risk, especially in post-menopausal women [19]. However, despite increasing 
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evidence, NNK is still considered a non-mammary carcinogen. Therefore, the role of tobacco 
carcinogens on breast cell carcinogenesis needs to be further investigated.  
 
Benzo[α]pyrene (B[α]P) 
 Benzo[α]pyrene (B[α]P) (Figure 1.6B)  is a five-ring aromatic polycyclic hydrocarbon 
generated from the incomplete combustion of organic materials [16]. B[α]P is known to be 
involved in human cancers of the lungs, skin and bladder and is classified  as a Group I 
carcinogen by the IARC since its metabolites are highly mutagenic and carcinogenic [17]. 
Metabolic activation of B[α]P is mediated by CYP1B1 [77]. B[α]P is found in coal tar, charcoal 
barbequed and wood-fire grilled foods, automobile exhaust (especially from diesel engines) and 
tobacco smoke [16, 42, 44]. Cooked meats have been shown to contain B[α]P [78] up to 5.5 ng/g 
in fried chicken [79] and 62.6 ng/g in well-done barbecued beef [80]. Therefore, B[α]P is 
considered both an environmental and dietary carcinogen.  
  B[α]P intercalates into DNA by covalently bonding to nucleophilic guanine bases at the 
N2 position causing distortion of the double-helix.  Perturbation of DNA structure disrupts 
normal DNA copying and induces mutations ultimately leading to cancer development following 
exposure [81]. B[α]P has been identified as a mammary carcinogen in rodents [63, 82, 83], and 
some studies have indicated that B[α]P may contribute to human breast cancer development 
because its metabolites form strong DNA adducts that cause DNA lesions [81, 83, 84]. However, 
the correlation between B[α]P exposure and breast cancer occurrence in women is modest [84-
86]. Therefore, B[α]P may be considered a weak mammary carcinogen in humans, but may play 
an important role in enhancement of precancerous carcinogenesis of human breast cells caused 
by other carcinogens.  
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2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP) 
2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP) (Figure 1.6C) is a 
heterocyclic amine (HCA) generated during the cooking of meats from the breakdown of 
creatine, amino acids and sugars [87]. PhIP is the most abundant HCA found in cooked meats 
and, as shown in Table 1.1, its abundance increases with cooking time and temperature with 
particularly high amounts found in well-done meats [26]. PhIP is a pro-carcinogen that requires 
metabolic activation through CYP1A2-mediated N-oxidation or O-acetylation mediated by 
polymorphic N-acetyltransferase 2 (NAT2) [26]. PhIP possesses high mutagenic activity 
compared to other HCAs because its structure (N-methyl group in the 1-position) makes it more 
available for interaction with the enzyme active sites of CYP1A2 and NAT2 resulting in higher 
rates of oxidation or acetylation, respectively [88]. The mutagenic potency of the resulting PhIP 
metabolites is 100-fold higher than those of related HCAs due to increased stability of the 
reactive intermediates and the resulting DNA adducts [88].  
PhIP is known to induce mammary cancer in rodents [25, 89-91] and its link to human 
cancers of the breast, colorectum and prostate is well established [26, 92-99]. Epidemiological 
studies have indicated a strong correlation between consumption of well-done meats and 
increased risk of breast cancer [26, 95, 96-98]. Risk of breast cancer development from PhIP 
exposure is particularly high in post-menopausal women and women possessing a NAT2 
polymorphism exhibiting high O-acetyltransferase activity [94, 95, 97, 99]. A study on PhIP-
DNA adducts in normal breast tissue of women with newly diagnosed breast cancer indicated 
that the extent of adduct formation was positively correlated with well-done meat consumption 




Human consumption of PhIP at microgram levels results in systemic exposure at pico to 
low nanomolar levels [25] and detection of PhIP as high as 59 pg/mL in the milk of healthy 
women indicates that ductal mammary epithelial cells are directly exposed to PhIP [100]. PhIP is 
known to induce activation mutations in the H-Ras proto-oncogene [25, 91] and exposure to low 
nanomolar doses of PhIP increased proliferation and activated the MAP kinase pathway in non-
cancerous immortalized human breast epithelial MCF10A cells [101]. This indicates that PhIP 
can stimulate the activation of oncogenic signaling pathways at levels close to human exposure 
[101].  
We are all exposed to multiple mutagenic agents, such as the ones described above, in 
our environment and diet each day. Since most breast cancers occur as a result of long-term 
carcinogen exposure, it is important to examine how multiple carcinogens act together to induce 
breast cell carcinogenesis. Additionally, further studies are needed to investigate how tobacco 
carcinogen NNK and weak human mammary carcinogen B[α]P can contribute to precancerous 
breast cell carcinogenesis.  
 
Hallmarks of Cancer 
The hallmarks of cancer consist of six biological capabilities acquired by cells during 
carcinogenic transformation (Figure 1.7) [102]. As normal cells become neoplastic, they 
successively acquire these hallmark characteristics enabling them to become tumorigenic and 
metastatic. These properties include sustaining proliferative signaling, evading growth 
suppressors, resisting apoptosis, enabling replicative immortality, inducing angiogenesis and 
activating invasion and metastasis [102].  
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Cancer cells can acquire the capacity to sustain proliferative signaling in a number of 
ways. They may over-express cell surface growth factor receptors, exhibit deregulation of 
growth factor signaling pathways, participate in paracrine proliferative signaling with normal 
cells in the stromal environment or participate in autocrine proliferative signaling in which 
cancer cells produce their own growth factor ligands [102]. Constitutive activation of 
proliferative signaling pathways often results in growth factor independence since there is no 
longer a need to stimulate these pathways by ligand-mediated receptor activation [102]. 
Enhancement of proliferative signaling may also result from defects in negative feedback 
mechanisms meant to attenuate signaling, such as those mediated by PTEN or mTOR [103].   
  To ensure continued growth, cancer cells must evade programs that negatively regulate 
proliferation, often through the action of tumor suppressors such as p53 or retinoblastoma protein 
(pRb). Anti-growth signals block proliferation by inducing cells to enter either a temporary 
quiescent state or a terminally differentiated post-mitotic state. During the G1 phase transition of 
the cell cycle, cells are actively monitoring their surrounding environment for external signals 
that will ultimately determine whether they will proliferate or enter into a quiescent or post-
mitotic state [102-103]. These signaling circuits can be disrupted in various ways in different 
types of tumors. In many cancers, mutations eliminate expression of p53 and pRb tumor 
suppressors, which play central roles in governing cell fate.  Loss of pRB results in deregulated 
proliferation and loss of p53 desensitizes cells to cell cycle checkpoints [104].  Some tumor cells 
lose responsiveness to anti-proliferative signals due to down-regulated, mutated or disrupted 
receptors. Additionally, tumor cells can turn off expression of integrins and other cell adhesion 
molecules that send anti-proliferative signals [102-103].  
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Apoptosis serves as a natural barrier to cancer development. During the course of 
tumorigenesis, cancer cells experience a variety of apoptosis-inducing stresses including 
hyperactive signaling by oncoproteins and DNA damage from hyperproliferation. The ability of 
tumor cells to evade the apoptotic program ultimately leads to high-grade malignancy and 
resistance to therapeutics [103]. The most common mechanism for avoiding apoptosis is through 
loss of the p53 tumor suppressor. In normal cells, p53 induces apoptosis in response to 
substantial DNA breaks and chromosomal abnormalities. However, p53-mediated DNA damage 
sensing machinery is often impaired in cancer which eliminates this critical component from the 
apoptosis-inducing circuitry [104]. Alternatively, tumor cells may evade apoptosis by increasing 
expression of anti-apoptotic regulators, such as Bcl-2, or decreasing expression of proapoptotic 
factors, such as Bax and Bim. Tumor cells may also increase production of survival signals, such 
as insulin growth factor 1/2 (Igf1/2), to circumvent activation of apoptotic machinery [103]. 
Cancer cells require unlimited replicative potential in order to form tumors. Normal cells 
are only able to pass through a limited number of division cycles before cells enter senescence, 
and ultimately crisis, which culminates in cell death. Cells that have avoided senescence and 
survive crisis are said to be immortalized and exhibit the capacity for unlimited replication. 
Telomeres protecting the ends of chromosomes are centrally involved in unlimited replicative 
potential. Telomeres usually shorten during each successive cell cycle leading to a loss in their 
protective functions, triggering entrance into crisis. Telomerase, a DNA polymerase that adds 
telomere repeat segments to the ends of chromosomal DNA, is over-expressed in immortalized 
cells, including cancer cells. Over-expression of telomerase is associated with resistance to 
senescence and crisis-associated cell death allowing cells to replicate indefinitely [103]. 
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During tumor progression, an “angiogenic switch” is almost always activated to induce 
the growth of tumor-associated neovasculature which provides tumor cells with nutrients and 
oxygen while allowing them to get rid of carbon dioxide and metabolic wastes. The best known 
angiogenic inducers and inhibitors are vascular endothelial growth factor-A (VEGF-A) and 
thrombospondin-1 (TSP-1), respectively, and regulation of angiogenesis depends on 
counterbalance between the two. Expression of VEGF-A and its associated receptors can be up-
regulated in tumor cells by oncogene signaling downstream of Ras or Myc and by hypoxia which 
often results from the high metabolic rates of cancer cells. Once angiogenesis is activated, other 
proangiogenic factors, such as members of the fibroblast growth factor (FGF) family, are 
chronically up-regulated to sustain tumor angiogenesis. A variety of other cell types have been 
implicated in tumor angiogenesis, such as many bone-marrow derived cells of the innate immune 
system including macrophages, neutrophils, mast cells and myeloid progenitors. These cells can 
infiltrate tumors where they help trip the usually dormant angiogenic switch [103].  
Progression of epithelial-derived carcinomas to higher pathological grades is 
characterized by local invasion and metastasis. In order to accomplish this, tumor cells must alter 
their attachment to other cells and to the extracellular matrix (ECM). As a result, expression of 
genes involved in cell-cell or cell-ECM adhesion, such as E-cadherin, are often down-regulated 
in carcinoma cells. Loss of E-cadherin or other adhesion molecules is known to potentiate 
invasive and metastatic phenotypes. Conversely, adhesion molecules associated with cell 
migration during embryogenesis and inflammation, such as N-cadherin, are often up-regulated. It 
has become clear that a normally inactive developmental regulatory program called the 
epithelial-to-mesencymal (EMT) transition program is involved in conferring cancer cells with 
invasive capabilities. The EMT program can become aberrantly activated in transformed 
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epithelial cells enabling them to acquire increased motility, invasiveness and dissemination 
[103]. The EMT program and its role in cancer will be discussed in further detail below. 
Since characterization of these six hallmarks of cancer in 2000 [102], several enabling 
characteristics and emerging hallmarks have been identified (Figure 1.8) [103]. Acquisition of 
the established hallmarks is made possible by two enabling characteristics, genomic instability 
and chronic inflammation. First, the development of genomic instability in cancer cells generates 
random gene mutations and chromosomal rearrangements which result in genetic changes that 
induce or enhance hallmark capabilities. In fact, the acquisition of most hallmark characteristics 
depends largely on genomic alterations in neoplastic cells. Besides mutations, epigenetic 
mechanisms such as DNA methylation or histone modifications can also contribute to cellular 
transformation. Essential to the orchestration of tumorigenesis is a breakdown in one or more 
components of the genomic maintenance machinery, such as p53, via inactivating mutation or 
epigenetic repression [103]. 
The second enabling characteristic is the inflammatory state of premalignant and 
malignant lesions driven by immune cells. Most tumors are densely infiltrated with cells of the 
innate and adaptive immune system that mimic inflammatory conditions in normal tissues. 
Ironically, this immune response meant to eradicate tumors from the body’s tissues often has the 
paradoxical effect of enhancing tumorigenesis. Inflammation can contribute to acquisition of 
hallmark capabilities by ensuring a steady supply of bioactive molecules, such as growth factors, 
proangiogenic factors and extracellular matrix-modifying enzymes, to the tumor 
microenvironment. Additionally, inflammatory cells can also release molecules, such as reactive 
oxygen species, that are actively mutagenic to tumor cells [103].  
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Two attributes of cancer cells have recently been recognized as being functionally 
important for cancer development and therefore may be considered as emerging hallmarks. The 
first is major reprogramming of cellular energy metabolism to support constant cell growth and 
proliferation. Non-cancerous cells usually rely on mitochondrial oxidative phosphorylation to 
produced ATP for cellular processes, initiating glycolysis only under anaerobic conditions. 
However, cancer cells can reprogram their energy production to fuel high glycolytic rates even 
when oxygen is present. This is known as the Warburg effect. Initially proposed as the 
underlying cause of cancer, it is now recognized to be a result of carcinogenic development. 
Since glycolysis is an inefficient method of ATP production, cancer cells must make up for this 
by increasing glucose uptake. Given this inefficiency, the benefit of this metabolic 
reprogramming to cancer cells is still unclear [103].  
The second emerging hallmark of cancer cells is the ability to evade immune destruction.   
Constant immune surveillance is responsible for recognizing and eradicating that vast majority of 
cancer cells, so any tumors that do form must have managed to escape detection by the immune 
system. As mechanisms of immunoevasion, tumor cells may release high levels of immuno-
suppressive factors, such as TGF-β, or recruit inflammatory cells that are actively immuno-
suppressive, such as regulatory T cells. In epidemiological studies, significant increases in 
certain types of cancers have been observed in immunocompromised individuals and high levels 
of killer lymphocytes is associated with better prognosis in colon and ovarian cancers [103].  
 
Precancerous Model of Cancer Progression 
Most breast cancers occur sporadically, often as a result from chronic exposure to low-
doses of carcinogens present in the environment and diet. It is important to study the agents that 
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contribute to sporadic breast cancers in order understand the mechanisms behind development of 
these diseases and to devise effective strategies for prevention. To address this need, we have 
developed a cellular model (Figure 1.9) that mimics chronic human breast cell carcinogenesis by 
repeatedly exposing non-cancerous human breast epithelial cells to low physiologically-
achievable pico to nanomolar concentrations of environmental and dietary carcinogens, such as 
NNK, B[α]P and PhIP, to imitate the carcinogen exposure encountered by people in their daily 
lives. Metabolites of NNK can be detected at picomolar concentrations in the body fluids of 
tobacco users [105] and metabolites of B[α]P can be detected at picomolar concentrations in 
human fat and liver [106]. Human consumption of PhIP at microgram levels results in systemic 
exposure at low nanomolar levels [25]. This model is used to reveal the potency of carcinogens 
to induce chronic carcinogenesis of breast cells by measuring progressive cellular acquisition of 
identifiable cancer-associated properties. These cancer-associated properties are then used as 
targeted endpoints to identify dietary agents that are capable of reducing cellular acquisition of 
these properties and suppressing carcinogenesis. Using this model, we repeatedly exposed 
immortalized, non-cancerous human breast epithelial MCF10A cells to NNK, B[α]P and/or 
PhIP, at pico or nanomolar concentrations, mimicking long-term exposure of breast tissues to the 
low but ever-present levels of carcinogens present in the environment and diet. A single 
exposure to these carcinogens induced transient biochemical, molecular and cellular changes 
which contributed to progressive acquisition of cancer-associated properties after cumulative 
exposures [107-115]. Importantly, our model highlights the relevance of using precancerous 





Detection of Cancer Progression 
Reduced Dependence on Growth Factors 
 A lack of growth factors causes normal cells to undergo cell-cycle arrest and apoptosis; 
however, transformed cells acquire a reduced dependence on growth factors (RDGF) to increase 
survivability [108-115]. The constitutive activation of proliferative signaling pathways 
downstream of growth factor receptors commonly seen in cancer cells eliminates the need for 
ligand-mediated activation of these receptors. This often results in cellular acquisition of growth 
factor independence conferring cancer cells with the ability to grow and proliferate without 
stimulation from external growth signals [102].   
 
Anchorage-Independent Growth 
 Anchorage of cells to the ECM is necessary for cellular survival in a multicell 
environment. Normal cells that fail to stay attached to the ECM undergo a programmed cell 
death response termed anoikis [116]. Anchorage-independent growth (AIG) aberrantly acquired 
to promote cell survivability can contribute to malignant transformation. Cellular acquisition of 
AIG is associated with phenotypic changes, such as the loss of contact inhibition and the ability 
to colonize in soft agar, and is correlated with increased tumorigenicity and invasiveness in 







 Cancerous cells acquire increased motility compared to their normal counterpart cells 
[117]. When cell monolayers are scratched or “wounded” in culture, cells at the wound margin 
respond to the disruption in cell-cell contacts by increasing their production of growth and other 
stimulatory factors to heal the wounded area by a combination of increased proliferation and 
motility [118,119]. Cancerous cells must acquire increased motility in order to migrate and 
invade surrounding tissues. In many cases, activation of the EMT program enables cancerous 
epithelial cells to acquire mesenchymal-like migratory capabilities [103]. Alternatively, some 
cancer cells may acquire the ability to migrate in an ameboid-like manner similar to leukocytes 
[117]. Increased cell motility in cancerous cells is closely related to the hallmark characteristics 
of cell migration and invasion discussed below. 
 
Migration and Invasion 
 The abilities of migration and invasion allow neoplastic cells to move through 
surrounding tissues, enabling their dissemination through the lymphatic and blood vasculature 
ultimately leading to metastatic growth in distant organs [120]. The capabilities for invasion and 
metastasis enable cancer cells to break free of the primary tumor biomass and successfully 
colonize new sites in the body. The acquired capacity for metastasis represents the final stage of 





Role of ERK Pathway in Cancer 
 The mitogen-activated protein kinase (MAPK) signaling cascade transmits and amplifies 
signals sent from cell surface receptors to downstream transcription factors to alter gene 
expression in response to external stimuli. MAPKs direct cellular responses to diverse signaling 
molecules, including growth factors, pro-inflammatory cytokines, steroid hormones, and G-
protein receptor mediated ligands, and are known to regulate genes involved in proliferation, 
differentiation and apoptosis. Three major MAPK pathways exist in humans, but the one 
involving Erk1/2 is the most relevant to breast cancer development [121]. Signal transduction 
from cell surface to nucleus requires multiple modulators in between. The Ras/Raf/Mek/Erk 
cascade (Figure 1.10) couples signals from receptor tyrosine kinases to transcription factors 
which regulate cell cycle progression [122]. 
 Binding of growth factors to receptor tyrosine kinases stimulates autophosphorylation of 
specific tyrosine residues on the receptor. The phosphorylated receptor then binds to the adapter 
protein GRB2, which in turn recruits SOS (son of sevenless) to the membrane. SOS is a guanine 
nucleotide exchange factor that displaces GDP from the Ras small GTPase, which allows for the 
binding of GTP. GTP binding activates Ras which then recruits and activates Raf. Raf initiates a 
protein phosphorylation cascade by first phosphorylating Mek1/2, which in turn phosphorylates 
Erk1/2. Phosphorylated Erk1/2 translocates from the cytoplasm to the nucleus where it 
subsequently phosphorylates a number of transcription factors, including Elk-1, which activate 
expression of specific sets of target genes. Ras activity is limited by the hydrolysis of GTP back 
to GDP by GTPase activating proteins. Ras is a well-known proto-oncogene and is known to be 
mutationally activated in about 30% of all human cancers [122]. 
 The involvement of MAPK activation in human breast cancer tissues was first 
29 
 
documented by Sivaraman et al. back in 1997 [123]. In comparing primary breast cancers with 
benign tissues using substrate based MAPK enzyme assays and immunoblotting methods, they 
found that all breast cancer tissues tested exhibited markedly high levels of activated MAPK. In 
1999, Sahl et al. [124] demonstrated the over-expression of activated Erk1/2 in human breast 
cancers. Using substrate based enzyme assays and immunoprecipitation studies, they detected up 
to a 2.5-fold increase in phosphorylated Erk1/2 in 50% of the breast tumors tested. Another study 
by Von Lintig et al. [125] investigated the mechanisms for up-regulation of MAPK signaling in 
breast tumors. They suggested that if the appropriate receptors are present, up-regulation of 
ligands may be responsible for elevated MAPK signaling in human breast cancers. This 
possibility is supported by the in vitro studies of Xing and Imagawa [126] who demonstrated that 
EGF could increase activated MAP kinase in primary cultures of mouse mammary cells. These 
studies, taken together, suggest that further correlation of activated MAP kinase with biological 
characteristics of tumors is warranted [121]. Studies have shown that high dose exposure to 
environmental carcinogens leads to ERK pathway activation [127], but whether low doses of 
environmental and dietary carcinogens can induce ERK pathway activation in breast cancer 
needs to be further clarified.  
 
Role of Reactive Oxygen Species in Cancer 
 Reactive oxygen species (ROS) are oxygen-containing, chemically-reactive molecules 
generated mainly in the mitochondria as a byproduct of oxidative phosphorylation during cellular 
respiration. ROS can be produced from endogenous sources, such as from mitochondria, 
peroxisomes, and inflammatory cell activation, or from exogenous sources such as chemical or 
environmental agents and pharmaceuticals. ROS include O2
-
-derived free radicals containing an 
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unpaired electron, such as superoxide anion radical (O2
-
) and hydroxyl radical (OH
-
), as well as 
nonradical derivatives of O2 such as hydrogen peroxide (H2O2) [128, 129].  
Chemical and physical agents that produce ROS can be involved in the initiation and 
modulation of the multistep carcinogenesis process. Various environmental agents including 
chlorinated compounds, phorbol esters, metal ions, barbiturates, radiation and acrylonitrile have 
been shown to induce oxidative stress during in vitro and in vivo studies. Oxidative stress may 
cause DNA, protein and lipid damage, leading to chromosomal instability, genetic mutation, and 
alteration of cell growth that may contribute to cancer development [129]. Oxidative DNA 
damage is a major source of mutations in living organisms, with more than one hundred 
oxidative DNA adducts having been identified [130-133]. Accordingly, several recent studies 
have demonstrated an important role for ROS in tumor development in various cancer types 
[134-137]. High-dose exposure to carcinogens has been shown to produce ROS in some studies 
[138-140], but the effect of low-dose environmental carcinogens in ROS production needs 
further evaluation. 
In addition to their effect on inducing oxidative stress and damage, ROS can also 
function as signaling molecules. Growing evidence suggests that the production of ROS is tightly 
regulated in mammalian cells and that these redox agents serve as intracellular signaling 
molecules involved in various pathways, including the Ras/ERK pathway. Although the 
mechanisms are not fully understood, ROS and Ras GTPase appear to exist in a feedback loop in 
which ROS function as effector molecules to stimulate Ras activation and Ras functions as a 
positive regulator of ROS production. Active Ras signaling can contribute to ROS generation via 
ERK pathway-mediated activation of NADPH oxidase (Nox) enzymes, which are the major 
source of ROS production outside of the mitochondria and will be discussed in further detail 
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below. ROS have been shown to promote Ras activation by stimulating dissociation of GDP and 
many small GTPases in the Ras superfamily were found to have redox-active motifs important 
for ROS-mediated regulation [141]. Additionally, Kerzee and Ramos demonstrated that 
activation of Ras by oxidative carcinogen metabolites involves a redox signaling mechanism 
[142]. ROS has also been shown to stimulate activation of the ERK pathway in a Ras-
independent manner via p38 MAPK in neutrophils [143]. The mutual interplay between ROS 
and the Ras/ERK pathway and its involvement in cancer development and progression represents 
a promising area in cancer research and warrants further investigation.  
 
NADPH-oxidase 1  
NADPH oxidases are a family of enzymes with seven isoforms (Nox-1-5 and DUOX1-2) 
that produce reactive oxygen species by transporting electrons across membranes, thereby 
reducing oxygen to superoxide. The Nox-1 isoform is expressed in a variety of cell types 
including epithelial cells, endothelial cells, retinal pericytes, osteoclasts and vascular smooth 
muscle cells [144], and has been implicated in the etiology of several diseases [144-150]. For 
instance, ROS produced by Nox-1 enzyme activity are known to function in angiotensin II-
mediated redox signaling pathways in vascular cells and thus participate in the pathogenesis of 
cardiovascular disease [145].  
Evidence is also mounting for the involvement of Nox-1 in various cancers. High 
expression of Nox-1 has been reported in cases of colon cancer where it may function to 
stimulate NF-kappaβ-dependent anti-apoptotic pathways in colon tumor cells [146,147].  Nox-1 
was also found to be highly expressed in breast and ovarian tumors, where deregulation of Nox-1 
redox signaling reportedly contributed to tumorigenesis [148]. More recently, Pervin et al. 
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demonstrated that oxidative stress induced through Nox-1 activity promotes breast tumor 
formation by down-regulating survivin, a member of the inhibitor of apoptosis (IAP) family that 
is highly expressed in aggressive triple-negative breast tumors and confers these tumors with 
increased survival, angiogenesis and drug resistance [149]. Over-expression of Nox-1 stimulated 
cell growth and proliferation and was found to induce a transformed phenotype in mouse 
fibroblasts, which translated to increased tumorigenicity in nude mice models [150]. 
Furthermore, Nox-1 was found to participate in the angiogenic switch by up-regulating VEGF 
expression and inducing matrix metalloproteinase activity, thus increasing the vascularity of 
tumors in a mouse model of prostate cancer [151]. Further research revealed that Nox-1 can also 
downregulate the expression and activity of the anti-angiogenic nuclear receptor peroxisome 
proliferator-activated receptor α (PPARα) and contributes to angiogenesis in mouse models of 
melanoma and Lewis lung carcinoma [144]. Since Nox-1 expression is induced through the Ras-
ERK pathway [152], it plays an important role in the interplay that occurs between ERK pathway 
activation and ROS production and may function to maintain and augment cancer-associated 
properties in breast epithelial cells. 
 
Cancer Stem Cells 
 Stem cells are distinguished from other cell types based on their ability to self-renew, 
sometimes after long periods of inactivity, and their capability to differentiate into specialized 
tissue-specific cell types. Stem cells undergo a special type of asymmetric cell division in which 
one of the daughter cells differentiates into a specialized cell type while the other retains stem 
cell capabilities. In this way, the pool of stem cells in the body remains constant [153]. The other 
defining property of stem cells is their “potency”, which refers to their ability to differentiate into 
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various types of specialized cells. Early embryonic stem cells are totipotent and able to give rise 
to any cell type in the body including placental cells. Later embryonic stem cells are pluripotent 
and able to give rise to any tissue type excluding placenta. Adult stem cells are considered to be 
multi- or unipotent and are able to develop into a few or only one type of cell, respectively [154]. 
 Cancer develops when normal cells aberrantly gain certain characteristics including stem-
like properties, such as existing in an undifferentiated state and exhibiting extensive self-renewal 
or “immortality” [153, 155]. The stem-cell model for cancer progression predicts that tumors 
consist of different cell types with different capacities for self-renewal and proliferation. 
Subsequently, only small subpopulations of stem-like cancer cells have the capacity to initiate 
tumor growth and reproduce the various cell types comprising the tumor [155].  
The past decade has accumulated tremendous evidence for the involvement of stem cells 
in cancer development. Cancer stem cells may arise from the mutational transformation of 
normal stem cells via aberrant activation of self-renewal promoting signaling pathways, or of 
differentiated cells via a process known as epithelial-to-mesenchymal transition (EMT), which 
will be discussed in further detail below [155]. It has been postulated that existing stem cells may 
be preferential targets of initial oncogenic mutations because they are the only long-lived 
populations in most tissues and are therefore exposed to more genotoxic stresses than their 
shorter-lived, differentiated progeny [153, 156]. Further support for the stem-cell model for 
cancer progression is provided by the observation of tumor heterogeneity: even though most 
tumors arise from a single cell, not all the cells within a tumor are identical suggesting that a 
single cell gave rise to different cell types [155, 156]. Additionally, cancer stem cells are highly 
enriched for the ability for reform tumors following transplantation relative to bulk tumor cells. 
Importantly, cancer stem cells often exhibit resistance to traditional chemotherapies, making it 
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necessary to kill or differentiate cancer stem cells in order to fully eradicate cancer [153, 155, 
156]. 
 
Mammary Stem Cells and Breast Cancer 
Although their involvement in cancer is virtually ubiquitous, stem cells have been 
extensively characterized in breast cancer development [155]. The mammary gland is a dynamic 
organ which undergoes significant developmental changes during puberty, pregnancy and 
lactation. Mammary stem cells provide the source of cells necessary for normal growth of the 
mammary gland during puberty and gestation but also play an important role in carcinogenesis of 
the breast [157-159]. The isolation and characterization of mammary stem cells has been 
hindered because of the scarcity of suitable markers and lack of adequate systems to maintain the 
stem cells in an undifferentiated state [158].  
A decade ago, Al Hajj et al. became the first to identify tumorigenic mammary stem cell 
markers [160].  They found that only a small population of breast cancer cells had the ability to 







cell surface marker expression and demonstrated their ability to generate 
tumors when injected into nude mice at numbers as low as 100 and to reproduce all the different 
types of cells present in mature tumors [160]. A major advancement in the field was achieved 
when Dontu et al. cultured mammary stem cells as anchorage-independent colonies in 
suspensions under low serum conditions, creating spheroids termed mammospheres [161], which 




Identification and Isolation of Mammary Stem Cells 
Recent advancements in stem cell research have made it possible to identify and isolate 
mammary stem cells at better efficiency than ever before. There are various markers and 
characteristics used to differentiate them from other surrounding cells. 
 
Mammospheres 
When grown in anchorage independent conditions, normal epithelial cells undergo a 
special type of apoptosis called anoikis that occurs when the cells are detached from the ECM 
[162]. However, when undifferentiated multi-potent populations of mammary cells are grown in 
suspension under low serum conditions, they form discrete spheroid clusters known as 
mammospheres. Mammospheres are enriched in progenitor cells and after several passages the 
mammosphere consists mostly of stem cells [161]. 
 
ALDH Activity 
 Ginestier et al. showed that normal and cancerous mammary epithelial cells exhibiting 
stem/progenitor properties also had increased activity of aldehyde dehydrogenase (ALDH), a 
polymorphic enzyme responsible for the oxidation of aldehydes to carboxylic acids. They found 
that high ALDH activity can be used to identify tumorigenic mammary cells capable of self-
renewal and of generating tumors that recapitulate the heterogeneity of the parental tumor. 
Additionally, high expression of ALDH in breast carcinomas was correlated with poor prognosis. 
This finding offers an important new tool for the study of normal and malignant breast stem cells 




Immunostaining and cell sorting based on surface marker expression is a widely used 
technique to enrich the population of stem cells. Stem Cell Antigen-1 (SCA-1) has been used to 
identify mammary stem/progenitor cells [164]. Mammary stem cells have also been identified 






which are seen to be over expressed in 
breast tumor cells [160]. 
  
Extensive self-renewal and multi-lineage differentiation 
 Stem cells derived from mammospheres have the capacity for extensive self-renewal and 
can differentiate into various types of cells. When they are grown on collagen under various 
conditions, such as in 2D culture systems, matrigel or in the presence of prolactin, these stem 
cells can generate the entire repertoire of cell types found in mammary tissue by differentiating 
into alveolar, acinar or ductal structures [158].  
 
Epithelial-to-Mesenchymal Transition 
Epithelial-to-mesenchymal transition (EMT) is a developmental regulatory program that 
can become aberrantly activated in transformed epithelial cells, conferring cells with increased 
migratory and invasive capabilities and stem-like properties [103]. EMT involves an orchestrated 
sequence of events in which cell-cell and cell-ECM interactions are disrupted to release 
epithelial cells into the surrounding tissue. The cytoskeleton is reorganized to facilitate 
movement through the ECM and a new transcriptional program is activated to maintain the 
mesenchymal phenotype [164]. During EMT, epithelial cells undergo multiple physical and 
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biochemical changes including alterations in morphology, cellular architecture, adhesion and 
migration capacity that enable them to assume a mesenchymal cell phenotype resulting in 
enhanced invasiveness, elevated resistance to apoptosis, and greatly increased production of 
ECM components [165]. Induction of the EMT program is detected primarily by measuring 
expression of associated molecular markers (Figure 1.11) including increased expression of N-
cadherin and Vimentin, nuclear localization of β-catenin, and increased production of 
transcription factors such as Snail, Slug, Twist, ZEB1/2 and E47 which inhibit production of E-
cadherin. Phenotypic markers for EMT include increased cell motility, migration and three-
dimensional invasion, as well as resistance to anoikis and apoptosis [166]. A summary of known 
EMT markers are listed in Table 1.2.  
Although induction of EMT has been shown to be highly tissue- and cell type-specific, 
some of the general cytoplasmic signal transduction pathways involved in EMT (Figure 1.12) 
have been fairly well defined [167]. The binding of the cytokine transforming growth factor-β 
(TGF-β) to its cell surface receptors induces EMT through activation and nuclear translocation of 
SMAD proteins which subsequently activate EMT-associated transcription factors Snail and 
ZEB1/2 [168]. In other cases, activation of EMT involves more pleiotropic signals. ROS 
produced through Nox-1 enzyme activity or in response to exposure to matrix metalloproteinases 
(MMPs) play a key role in EMT by modulating signaling pathways involved in cell adhesion and 
migration resulting in disruption of cell-cell adhesion, redistribution of E-cadherin, deregulation 
of integrins and eventual loss of the epithelial phenotype [165, 169]. Several other oncogenic 
signaling pathways including Src, Ras-MAPK, Wnt/beta-catenin and Notch have also been 
implicated in EMT [170, 171]. In particular, Ras-MAPK has been shown to activate two related 
transcription factors known as Snail and Slug, both of which are transcriptional repressors of E-
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cadherin and known to be involved in EMT induction [172]. Additionally, studies have shown 
that activation of the phosphatidylinositol 3' kinase (PI3K)/AKT cascade may be a central 
modulator of EMT due to its involvement in regulation of E-cadherin gene expression and 
subcellular localization [173]. Since EMT enables transformed epithelial cells to acquire the 
mesenchymal traits that facilitate metastasis, it has therefore been associated with aggressive 
breast cancer subtypes and poor clinical outcome. 
 
EMT and Cancer Stem Cells 
EMT is associated with dedifferentiation of epithelial cells and has been shown to 
generate cells with stem-like properties. In 2008, Mani et al. reported that the induction of EMT 
in immortalized human mammary epithelial cells (HMLEs) resulted in the acquisition of 
mesenchymal traits and the expression of stem cell markers [174]. Additionally, they found that 
stem-like cells isolated from human mammary glands or mammary carcinomas expressed EMT-
associated markers. Furthermore, transformed human mammary epithelial cells that have 
undergone EMT have enhanced ability form mammospheres, soft agar colonies and tumors. 
These findings illustrate a direct link between the induction of EMT and the acquisition of 
epithelial stem-like properties [174]. 
Several studies have suggested the importance of environmental carcinogens in activation 
of EMT [175-177] and generation of cancer stem cells [178]. The ability to identify and target 
cancer stem cells in therapy is a fast growing research area; therefore it is important to identify 
the origin of cancer stem cells and role of EMT during the precancerous stages of cancer 
progression induced by chronic exposure to environmental and dietary cracinogens. This may 
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help to prevent the formation of cancer stem cells and might be a powerful tool in reducing the 
risk of cancer occurrence and relapse in patients.  
 
Dietary Cancer Prevention 
 Broad geographical variation in breast cancer incidence and mortality rates is thought to 
be the result of differences in lifestyle and environmental factors, including diet [179, 180]. 
Dynamic studies that link changes in cancer occurrence within countries to environmental or 
dietary changes have suggested that diet and other lifestyle factors can substantially influence 
cancer risk [181]. According to Doll and Peto, dietary factors may contribute to an estimated 
one-third of all cancer-related deaths [179]; however, this estimate can vary from 10% to 70% 
[182]. The World Health Organization has estimated that at least 30-40% of all cancer-related 
deaths are preventable [183]. Numerous studies have indicated that high intake of fruits and 
vegetables is associated with decreased risk of various cancers including pancreatic, lung, colon, 
breast, cervical, esophageal, oral, stomach and bladder [184]. 
 Naturally-occurring agents in dietary sources have been intensely investigated for the 
intervention of various diseases including cancer due to their low toxicity and ease of availability 
[185]. Research over the last decade has identified multiple bioactive compounds in fruits and 
vegetables that can reduce the occurrence of various cancers [186]. Given the important role of 
diet in cancer prevention, effective and practical chemopreventive strategies need to be 





Chemopreventive Compounds in Fruit, Vegetables, Spices and Tea 
Prevention of cancer through use of chemical intervention regimes, or 
“chemoprevention”, is an emerging field with broad implications for influencing cancer 
incidence especially among high risk groups. Many potentially chemopreventive compounds 
have been identified in dietary sources, some of which are listed in Table 1.3. Fruits, vegetables, 
spices and tea contain classes of primary metabolites such as vitamins (vitamin C, vitamin D, 
pro-vitamin A, folate) and minerals (calcium, magnesium, selenium, zinc) as well as secondary 
metabolites such as phytochemicals (flavonoids, carotenoids, phenolics polyphenols, terpenoids, 
alkaloids) that behave as bioactive molecules and provide substantial health benefits beyond 
basic nutrition [186, 188]. These molecules can block any stage of the multi-step oncogenic 
process by exerting antioxidant, anti-proliferative, anti-inflammatory, anti-angiogenic or pro-
apoptotic effects, mediated by various signal transduction pathways (Figure 1.13) [188].  
Carotenoids, such as beta-carotene and lycopene, are commonly found in orange- or red- 
pigmented vegetables and fruits including sweet potatoes, carrots, pumpkin, tomatoes, red 
peppers, papaya, mango and cantaloupe [186]. Other carotenoids, such as leutin, are found in 
dark leafy greens such as spinach and kale. Carotenoids act as chemopreventive agents through 
biological activities such as antioxidant activity, immune enhancement, protection against 
cellular mutagenesis, or cell cycle arrest, but evidence for their involvement in breast cancer 
prevention has been inconclusive [188]. Organosulfur compounds, such as dithiolthiones and 
isothiocyanates found in cruciferous vegetables like broccoli, cabbage and cauliflower, and 
diallyl sulfides and allyl methyl trisulfides found in onions, garlic, leeks and chives, can increase 
the activity of enzymes involved in the detoxification of carcinogens, prevent DNA adduct 
formation and induce cell cycle arrest. These compounds have shown promise as preventive 
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agents against breast cancer as they have demonstrated anti-proliferative and pro-apoptotic 
effects on breast cancer cells [188, 189]. The antioxidants vitamin C, found in citrus fruits, 
papaya, strawberries, bell peppers, kale and broccoli, and vitamin D, found in mushrooms, dairy 
products and cereals, protect cell membranes and DNA from oxidative damage. Vitamin C may 
further help prevent cancer via its ability to scavenge and reduce nitrite, thereby reducing 
substrate for the formation of nitrosamines [190]. Curcumin, a naturally-occurring pigment and 
major component of the spice turmeric, possesses potent antioxidant and anti-inflammatory 
activity and prevents carcinogenesis by inhibiting genes associated with proliferation and 
metastasis, inducing cell cycle arrest or inducing apoptosis. Curcumin had been shown to be 
effective in preventing prostate and colorectal cancers; however, its therapeutic effects on breast 
cancer remain to be determined [188]. 
Flavonoids, such as querticin, kaempferol and catechins, are polyphenolic antioxidants 
most commonly found in fruits, tea, soybeans and wine [188]. In addition to their antioxidant 
activity, flavonoids also protect against carcinogens by increasing the pump-mediated efflux of 
certain carcinogens from cells [191] or by inducing detoxification enzymes [192]. Soybeans 
contain genistein, an isoflavonoid and phytoestrogen that has been shown to reduce the risk of 
breast cancer by decreasing the activation of carcinogens or by acting as a negative regulator of 
protein tyrosine kinase and estrogen receptor signaling in breast cancer cells [188]. Fruit, 
vegetables, and legumes are also major sources of dietary fiber, which has been widely accepted 
as a dietary protective agent against colon cancer [193]. 
 Various dietary sources have different bioactive compounds that help prevent cancer 
through diverse mechanisms. Therefore, a balanced diet is recommended for cancer prevention 
[194]. In this study we have examined the importance of the green tea catechins (-)-epicatechin-
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3-gallate (ECG) and (-)-epigallocatechin-3-gallate, as well as the plant sterol ergosterol and the 
rare plant amino acid mimosine in the prevention of chronic breast cell carcinogenesis. 
 
Green Tea 
Green tea is made from leaves of the Camellia sinesis plant that have undergone little to 
no oxidation during processing. It is the most globally consumed beverage in the world after 
water and is a traditional drink in many Asian countries, but is also popular in North Africa, the 
United States and Europe [195, 196]. Green tea contains characteristic polyphenolic compounds 
called catechins. The four major catechins present in green tea are (-)-epigallocatechin-3-gallate 
(EGCG), (-)-epigallocatechin (EGC), (-)-epicatechin-3-gallate (ECG), and (-)-epicatechin (EC) 
in a typical composition of 10-15% EGCG, 6-10% EGC, 2-3% ECG, and 2% EC [196]. The 
polyphenolic structure of green tea catechins (GTCs) allows electron delocalization to quench 
free radicals including reactive oxygen species. GTCs are also strong chelators of free metal ions 
which prevents the formation of ROS [197].  
Accumulating evidence from animal studies has demonstrated that tea and tea 
polyphenols have an inhibitory effect on tumor formation and growth in various organs including 
the mammary gland [198-202]. GTC extract is able to suppress rat mammary carcinogenesis 
induced by 7,12-dimethylbenz[α]anthracene and N-methyl-nitrosourea and exhibits anti-
proliferative and pro-apoptotic effects in human breast cancer cells in vitro [200, 201]. The 
inhibitory function of GTCs is associated with antioxidant activity, decreased cell proliferation, 
increased apoptosis and suppression of angiogenesis [197]. Epidemiological studies have not yet 
yielded conclusive evidence on the protective effect of tea consumption against the development 
of cancer in humans [197, 203-206], however some epidemiological and clinical data suggests 
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that regular consumption of GTCs can suppress breast cancer recurrence and development of 
colon cancer from premalignant lesions [207-209].  
Although EGCG is the most commonly studied preventive GTC [197], some studies have 
shown that ECG can be more effective than EGCG in intervention of carcinogenesis using 
various cellular models [112, 210, 211]. In the present study, we examined the preventive 
activity of ECG and EGCG individually and in combination to suppress breast cell 
carcinogenesis chronically induced by combined environmental and dietary carcinogens. ECG 
and EGCG have similar molecular masses, 442.37 and 458.37 g/mol respectively, indicating 
similar absorption efficiencies that will result in comparable bioavailability [197]. Since ECG is 
present in much lower concentrations than EGCG in green tea or green tea extract, additional 
supplementation with pharmacological concentrations of ECG may be considered for long-term 
prevention of breast cancer.   
 
Epicatecin-3-gallate (ECG) 
Like all catechins, epicatechin gallate (ECG) is a flavan-3-ol with four additional 
hydroxyl groups and two chiral carbons (Figure 1.14A). ECG can intervene in multiple cell 
signaling pathways and has various molecular targets, which likely act together to reduce the risk 
of carcinogenesis. The anti-carcinogenic mechanisms of ECG include inhibition of CYP450 
enzymes that metabolize carcinogens to active compounds, activation of detoxification and 
antioxidant enzymes, arrest of cell cycle progression, induction of pro-apoptotic and anti-
inflammatory signaling and mediation of metastasis [212-216]. Many of these effects may be due 
to its direct or indirect interaction with numerous molecular targets such as NSAID activated 
gene-1 (NAG-1), activator protein 1 (AP-1), 5α-reductase and platelet derived growth factor 
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(PDGF) [217]. By chelating copper and zinc metals ions, ECG may also inhibit the enzymatic 
activity of RNase A and MMPs, which are important cofactors for angiogenesis and metastasis. 
Structure and function analysis revealed that the gallate moiety of ECG is important for 
mediating these inhibitory effects and may enhance its chemopreventive ability [216]. 
 
Epigallocatechin-3-gallate (EGCG) 
Epigallocatechin-3-gallate (EGCG) is the ester of epigallocatechin and gallic acid 
(Figure 1.14B). EGCG is the major component of the polyphenolic fraction of green tea 
accounting for approximately 15% of the overall catechin content [197]. EGCG is a potent 
scavenger of free radicals which protects cellular components from oxidative damage and a 
number of studies have demonstrated its anti-mutagenic, anti-tumorigenic, anti-angiogenic, anti-
proliferative and pro-apoptotic effects on mammalian cells in vitro and in vivo. Increasing 
evidence indicates that EGCG can be effective against brain, prostate, cervical and bladder 
cancers [218-220]. Research suggests that EGCG may suppress carcinogenesis through 
inhibition of MAP kinases and growth factor-mediated cell signaling, and activation of AP-1, 
nuclear factor-B (NF-kappaB), topoisomerase I and MMPs [221]. EGCG has also been shown to 
inhibit the anti-apoptotic protein Bcl-xl, which has been implicated in cancer cell survival [222].  
Therefore, EGCG is a dynamic anticancer agent which provides convincing evidence to support 








 Wild-growing and cultivated mushrooms are consumed in many countries around the 
world often as a delicacy. Ergosta-5,7,22-trien-3β-ol, or simply ergosterol, is a sterol found 
exclusively in fungi and forms the major constituent of the fungal cell membrane serving the 
same purpose as cholesterol in animal cells (Figure 1.15A) [223]. Ergosterol is a provitamin that 
is converted by UV irradiation to Vitamin D2; subsequently, mushrooms exposed to UV light 
contain 2-4 times the Food and Drug Administration’s daily recommendation of Vitamin D 
[224]. Common dietary sources of ergosterol include mushrooms of the Agaricus bisporus 
(white button or portobello), Lentinula edodes (shiitake), Pleurotus ostreatus (oyster mushroom) 
and Tuber (truffle) species [223], as well as products made with yeasts such as soy sauce, bread 
and beer [225-227].  
Ergosterol and its derivatives, including ergosterol peroxide, possess immunosuppressive, 
anti-inflammatory, anti-viral and anticancer activities in vitro and in vivo. High mushroom intake 
is associated with lower risk of cardiovascular disease due in part to the anti-inflammatory and 
antioxidant effects of ergosterol [228]. There is solid evidence for the potential of ergosterol as 
an anticancer agent. In a two stage experimental carcinogenesis study, ergosterol extracted from 
Japanese edible mushroom Hypsizigus marmoreus exhibited inhibitory effects against 12-O-
tetradecanoyl-phorbol-13-acetate (TPA)-induced ear and skin inflammation and tumor 
promotion in mice [229, 230]. Ergosterol peroxide suppressed the proliferation rates of a variety 
of tumor cell lines by up to 40% [231]. Ergosterol has also been identified as a protective agent 
against the promotion of carcinogen-induced bladder tumors in rats [232].  
The mechanism of ergosterol’s anticancer activity has not been fully elucidated, but is 
thought to be due in part to direct inhibition of angiogenesis in solid tumors. Using two in vivo 
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models, Takaku et al. showed that intraperitoneal administration of ergosterol inhibited 
neovascularization in a mouse model of Lewis lung carcinoma and in female C57BL/6 mice 
injected subcutaneously with Matrigel containing proangiogenic factors [233]. Ergosterol 
peroxide was also shown to inhibit angiogenesis in multiple myeloma cells by targeting the 
JAK2/STAT3 signaling pathway and inhibiting subsequent activation of VEGF [234]. Moreover, 
ergosterol peroxide and ergosterol were found to suppress the growth of colon adenocarcinoma 
cells through inhibition of MAPK phosphorylation and block lipopolysaccharide (LPS)-induced 
inflammatory responses in macrophages through inhibition of NF-κB transcriptional activity 
[235]. Additionally, these compounds have exhibited cytotoxicity against human pancreatic and 
breast cancer cell lines [236]. There is also evidence that ergosterol peroxide may attenuate 
microRNA-mediated chemoresistance in tumor cells by selectively killing aggressive cancer 
cells [237]. However, there is scarcity of knowledge regarding the ability of ergosterol to act as a 
preventive agent against the development of breast cancer. 
 
Mimosine 
 Mimosine (β-[N-(3-hydroxy-4-oxypyridyl)]-R-aminopropionic acid), also known as 
leucenol, is a rare alkaloid amino acid found exclusively in tropical legumes of the Mimosa and 
Leucaena genera. It is a non-proteinogenic, plant-origin, free amino acid structurally analogous 
to tyrosine (Figure 1.15B) that can cause toxicosis in non-ruminant animals at high 
concentrations by causing renal and liver failure [238]. The leaves, seeds and fruits of various 
Leucaena species are widely consumed throughout India, Indonesia, Central America and 




 Some of the mechanisms by which mimosine exerts its toxic action may be responsible 
for its anticancer effects. Mimosine is an iron chelator that inhibits DNA synthesis and causes 
cell cycle arrest in late G1 phase [238]. Mimosine arrests cell cycle progression at the G1-S phase 
border prior to the onset of DNA replication [240]. Several mechanisms have been proposed to 
explain the effects of mimosine on blocking cell cycle progression. At high micromolar 
concentrations, mimosine has been shown to specifically inhibit expression of cyclin D1 and to 




 cyclin-dependent kinase (CDK) 
inhibitors [241, 242]. Subsequently, high doses of mimosine have been effective in reducing the 
proliferation rates of several types of cancer cell lines including lung [241], cervical [243], 
prostate [244] and breast cancer cells [245], as well as reducing tumor growth in vivo in mouse 
xenograft models of human non-small cell lung carcinoma [246] and pancreatic cancer [247]. 
 The metal chelating function of mimosine is closely associated with its toxicity and anti-
proliferative effects. Iron chelation by mimosine disturbs the action of metal-containing enzymes 
causing inhibition of some biological reactions [239] including translation of mRNA [243] and 
the initiation and elongation steps of DNA replication [248]. Accordingly, inhibition of DNA 
synthesis by the iron chelating function of mimosine was found to block cell cycle progression in 
breast cancer cells [245] and induce apoptosis in mouse leukemia cells [249] and human 
pancreatic cancer cells [247]. Although much research has focused on the use of high doses of 
mimosine to block proliferation or induce apoptosis in cancer cells, little work has been 






Cancer Prevention Strategies using Combined Dietary Agents 
 Prevention strategies making use of combined dietary agents with different molecular 
mechanisms are advantageous over those using individual agents due to higher efficacy and 
lower toxicity. Since carcinogenesis occurs in multiple stages, a variety of agents with distinct 
modes of action targeting different signaling pathways are needed to effectively suppress this 
complex process. Accordingly, there are many lines of evidence that support the use of combined 
dietary agents for the prevention of various malignancies. For instance, consuming a variety of 
chemopreventive agents from fruits, vegetables and soy is associated with decreased risk of 
breast cancer among postmenopausal women in Singapore [251] and combining vitamin E with 
vitamin C or β-carotene more effectively reduced UV-induced skin inflammation in human trials 
and is associated with decreased risk of melanoma and non-melanoma skin cancers [252].  
 Dietary phytochemicals can inhibit or delay carcinogenesis by displaying antioxidant 
activity, regulating inflammatory or proliferative signaling, or by inducing apoptosis. Therefore, 
one effective strategy for cancer prevention is to combine dietary agents with differing methods 
of antioxidant activities, such as combining molecules which scavenge ROS with molecules that 
prevent generation of ROS. Combining 1-acetoxychavicol acetate (ACA), a phenylpropanoid 
occurring in the rhizomes of Alpinia galangal which is consumed in Southeast Asia, with 
superoxide dismutase (SOD), an ROS-scavenging enzyme present in cereal grains and 
cruciferous vegetables, synergistically suppressed ROS generation in inflammatory leukocytes 
compared to individual agents. The high efficacy of this combination is due to the 
complementary effects of ACA, which prevents ROS generation by inhibiting Nox family 
enzymes, and SOD which neutralizes ROS [253]. Similar results were seen with ACA/caffeic 
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acid, EGCG/SOD, EGCG/ genistein, EGCG/benzyl isothiocyanate and benzyl isothiocyanate/ 
genistein combinations [250, 253].  
 Another effective strategy is to combine dietary agents with complementary anti-
inflammatory functions. In a rat model of human prostate cancer, animals fed a combination of 
soy protein and green tea had reduced occurrence of prostate malignancy markers and 
hyperplasia, lower number of inflammatory cells infiltrated into the prostate and decreased 
protein expression of inflammatory cytokines in the prostate. Interestingly, none of these effects 
were seen in animals fed individual agents. Mechanistically, Hsu et al. found that the soy/green 
tea combination suppressed prostate cancer development by mitigating chronic inflammation 
through modulation of NF-kappaβ signaling. Bioactive compounds in green tea decreased the 
DNA binding activity of the p50 subunit of NF-kappaβ and bioactive compounds in soy restored 
levels of the NF-kappaβ inhibitor p-IκBα to that of the control group [254]. Paradoxically, green 
tea catechin EGCG has also been shown to increase inflammatory cytokines produced by 
RAW264.7 macrophages. However, the cytokine-inducing properties of EGCG were completely 
masked by combined treatment with the soybean isoflavonoid genistein resulting in marked 
suppression of pro-inflammatory signaling [250]. This result highlights another important 
advantage of combination strategies; combining one dietary agent with another can abolish or 
attenuate potential side-effects while still increasing efficacy.    
 A third common and effective strategy is to combine dietary agents that can increase 
apoptotic death in cancer cells. In the rat model of prostate cancer mentioned above, Hsu et al. 
also found that the rats fed the soy/green tea combination showed increased apoptotic signaling 
in prostate tissues compared to animals fed individual agents. The combination of soy and green 
tea resulted in increased expression of pro-apoptotic Bax and decreased expression of anti-
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apoptotic BcL-2 and cellular inhibitor of apoptosis 1 (cIAP-1) [254]. In another animal model of 
prostate cancer, TRAMP (transgenic adenocarcinoma of the mouse prostate) mice fed a 
combination of tomato powder and soy germ showed increased apoptotic index (AI) in the 
prostate epithelium contributing to reduced prostate cancer incidence compared to mice fed 
individual agents [255]. In vitro experiments using normal and cancerous human colon cell lines 
revealed that combinations of indoles and isothiocyanates from cruciferous vegetables more 
effectively induced apoptosis in colon cancer cells, but not in normal cells, when compared to 
individual agents. Interestingly, a combination of indole and isothiocyanate agents also markedly 
reduced DNA damage caused by B[α]P [256]. 
 Numerous other strategies have been designed to maximize cancer suppression by 
exploiting the various preventive mechanisms of dietary agents. Zhou et al. determined that tea 
and soy combinations contribute to breast and colon cancer prevention by targeting various 
metabolic syndrome elements in mice in a synergistic manner resulting in reprogramming of 
aberrant metabolic signaling [257]. Other research has indicated that a combination of 
polyphenols from green tea and sulforaphane from cruciferous vegetables, which inhibit DNA 
methyltransferases (DNMTs) and histone deacetylases (HDACs) respectively, results in 
epigenetic modifications that reactivate ERα-receptor signaling in ERα-negative breast cancer 
cells conferring them with increased drug sensitivity [258]. In a rat model of colorectal cancer, a 
combination of green tea and selenium was more effective in decreasing aberrant crypt foci 
formation and all tumor-associated endpoints through targeting different cellular responses to 
oncogenic DNA lesions [259]. In the present work, we propose that a combination of dietary 
agents is the best course of action against breast cell carcinogenesis induced by multiple 
environmental and dietary agents.  
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PhIP content in cooked meats  
Meat type Cooking variation PhIP ng/g +/- SD 
 
Beef (1.5 cm thick) 
Fried – medium rare  (51ºC) 0.29 +/- 0.14 
Fried – well-done (63ºC) 0.73 +/- 0.02 
Fried – very well-done (74ºC) 7.33 +/- 0.11 
Lamb Chop 
Fried – medium (75ºC) 0 
Fried – well-done (85ºC) 2.4 
Pork (2 cm thick) 
Fried – medium (63ºC) 0.37 +/- 0.06 
Fried – well-done (83ºC) 7.82 +/- 1.13 
Mince Beef Patty (2 cm thick) Fried – medium (51ºC) 0 
Fried – well-done (58ºC) 3.96 +/- 0.13 
Chicken (2.5 cm, no skin) 
Fried – lightly browned (63ºC) 0.2 +/- 0.005 
Fried – well-done (79ºC) 17.54 +/- 0.17 
Sausage Fried – lightly browned (42ºC) 0 
Fried – well browned (70ºC) 0.61 +/- 0.06 
Bacon, middle Fried – lightly cooked 0.11 +/- 0.002 









List of known EMT markers 




Snail1 (Snail) Proteins that accumulate in the nucleus 
Snail2 (Slug) β-catenin 
Twist Smad-2/3 
FOXC2 NFκB 
Sox10 Snail1 (Snail) 
MMP-2 Snail2 (Slug) 
MMP-3 Twist 
MMP-9 In vitro functional markers 
Integrin αvβ6 Increased migration 
Proteins that decrease in abundance Increased invasion 
E-cadherin Increased scattering 
Desmoplakin  Elongation of cell shape 










List of chemopreventive compounds and their common sources 
Preventive Compound Source 
Allium Compound Onions, garlic, scallions, leeks, chives 
Carotenoids Carrots, sweet potatoes, tomatoes, dark leafy greens 
Coumarins Tonka beans, mullein, cassia, cinnamon, sweet clover 
Dietary fiber Soybeans and other legumes 
Flavonoids Green tea, wine, citrus fruits, dark chocolate 
Folic acid Green leafy vegetables, cereals 
Indole-3-carbinal Broccoli, cabbage, cauliflower, Brussels sprouts, collard greens, kale 
Isoflavones Soybeans, green beans, alfalfa sprouts, cowpeas 
Isothiocyanate Horseradish, mustard, radish, Brussels sprouts, watercress, capers 






































































Figure 1.6  
Chemical structure of carcinogens 
(A) Structure of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) 
(B) Structure of benzo[α]pyrene (B[α]P) 
(C) Structure of 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP) 
 




































































































Chemical structure of green tea catechins 
(A) Structure of (-)-epicatechin-3-gallate (ECG) 













Chemical structure of ergosterol and mimosine  
(A) Structure of ergosta-5,7,22-trien-3β-ol (ergosterol) 



















Chronic Exposure to Combined Carcinogens Enhances Breast Cell 




Research described in this chapter is a slightly modified version of an article that has been 
accepted for publication in PLoS ONE by Lenora Ann Pluchino and Hwa-Chain Robert Wang 
 
Lenora Ann Pluchino and Hwa-Chain Robert Wang. Chronic Exposure to Combined 
Carcinogens Enhances Breast Cell Carcinogenesis with Mesenchymal and Stem-like Cell 
Properties. (PLoS ONE, Accepted) 
 
In this paper “our” and “we” refers to me and co-authors. My contribution in the paper includes 
(1) Selection of the topic (2) Compiling and interpretation of the literature (3) Designing 
experiments (4) understanding the literature and interpretation of the results (5) providing 






Most breast cancers occur sporadically due to long-term exposure to small quantities of 
multiple carcinogens present in the environment and diet via a multi-step process involving the 
progressive transformation of cells from a non-cancerous stage to pre-cancerous and cancerous 
stages. To understand how multiple carcinogens act together to induce cellular carcinogenesis, 
we studied the activity of environmental carcinogens 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-
butanone (NNK) and benzo[α]pyrene (B[α]P), and dietary carcinogen 2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine (PhIP) using our breast cell carcinogenesis model. Our study 
revealed, for the first time, that combined NNK and B[α]P (NB) enhanced breast cell 
carcinogenesis chronically induced by PhIP in both non-cancerous and cancerous breast cells. 
Co-exposure to NB and PhIP was more potent than sequential exposure to NB followed by PhIP 
in initiating and progressing carcinogenesis. Initiation of carcinogenesis was measured by 
transient endpoints induced in a single exposure, while progression of carcinogenesis was 
measured by acquisition of constitutive endpoints after cumulative exposures.  Transient 
endpoints included DNA damage, Ras-ERK-Nox pathway activation, reactive oxygen species 
elevation, and increased cellular proliferation. Constitutive endpoints included various cancer-
associated properties and signaling modulators, as well as enrichment of cancer stem-like cell 
population and activation of the epithelial-to-mesenchymal transition program. Using transient 
and constitutive endpoints as targets, we detected that a combination of the green tea catechins 
ECG and EGCG, at non-cytotoxic levels, was more effective than individual agents in 
intervention of cellular carcinogenesis induced by combined NNK, B[α]P, and PhIP. Thus, use 
of combined ECG and EGCG should be seriously considered for early intervention of breast cell 




Breast cancer is the most common type of cancer and second leading cause of cancer-
related death among women in North America and Europe [1,2]. Over 85% of breast cancers 
occur sporadically due to long-term exposure to low doses of multiple carcinogens [3–7]. This 
chronic disease process involves cumulative genetic and epigenetic alterations which 
progressively transform cells from a non-cancerous stage to pre-cancerous and cancerous stages 
[3-6]. Since we are all exposed to various environmental and dietary carcinogens each day, it is 
important to investigate how multiple carcinogens act together to induce cellular carcinogenesis. 
We have developed a cellular model that mimics breast cell carcinogenesis induced by 
cumulative exposures to physiologically-achievable doses of environmental and dietary 
carcinogens to understand the cellular, biochemical, and molecular changes involved in cellular 
carcinogenesis for the purposes of intervention.   
 American lifestyles involve frequent consumption of high-temperature cooked meats 
containing carcinogens, such as 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), and 
wide exposures to smoke and polluted air containing 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone (NNK) and benzo[α]pyrene (B[α]P).  PhIP is the most abundant heterocyclic amine 
found in meats cooked at high temperatures, and consumption of PhIP at microgram levels 
results in systemic exposure at low nanomolar levels [8,9].  Gastric administration of PhIP 
induces mammary tumors in rats [10,11], and epidemiological studies have indicated a close 
association between well-done meat consumption and human breast cancer risk [12–14].  NNK, 
a tobacco-specific nitrosamine ketone, can be detected at picomolar concentrations in body fluids 
of tobacco users [15–17].  Although gastric administration of NNK into rats resulted in DNA 
adducts and tumor development in the mammary gland [18,19], NNK is not recognized as a 
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mammary carcinogen.  The link between smoking and breast cancer is controversial; however, 
recent studies indicate that exposure to tobacco smoke can increase breast cancer risk, especially 
in post-menopausal women [20–22].  Thus, the role of tobacco carcinogens in breast cancer 
needs to be clarified.  B[α]P, on the other hand, is recognized as a weak mammary carcinogen. 
B[α]P is a polycyclic aromatic hydrocarbon present in carbon exhaust, charcoal-barbequed 
foods, and tobacco smoke; it can be found in picomolar concentrations in human fat and liver 
[23–28]. 
 Our studies have shown that NNK at100 pmol/L, B[α]P at 100 pmol/L, and PhIP at 10 
nmol/L are able to induce initiation and progression of breast cell carcinogenesis [29–35].  A 
single exposure to these carcinogens induces transient changes, which play essential roles in the 
induction of carcinogenesis and can be used as transient endpoints to promptly reveal 
carcinogenic activity.  Cumulative exposures to carcinogens progressively induce cellular 
acquisition of various cancer-associated properties and activation of associated pathways; these 
properties are measurable constitutive endpoints used to determine the progression of cellular 
carcinogenesis [29–35].  Our model also reveals increases of cancer stem-like cell populations 
and activation of the epithelial-to-mesenchymal transition (EMT) program during carcinogen-
induced cellular carcinogenesis [35,36].  Development of cancer stem-like cells, involving 
induction of the EMT program, plays an important role in generating and maintaining pre-
malignant and malignant lesions [37].  Thus, we also used increased cancer stem-like cell 
population and induced EMT program as constitutive endpoints in our studies.  We then used 
these endpoints as targets to identify preventive agents, such as green tea catechins (GTCs) 
epicatechin (EC), epicatechin-3-gallate (ECG), epigallocatechin (EGC), and epigallocatechin-3-
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gallate (EGCG), at non-cytotoxic levels, capable of intervening in breast cell carcinogenesis 
induced by NNK, B[α]P, or PhIP [31–36].   
 In this communication, we report the potency of co-exposure versus pre-exposure to 
combined NNK and B[α]P (NB) with PhIP in chronic induction of breast cell carcinogenesis.  
Co-exposure to NB and PhIP (NBP) induced higher levels of transient and constitutive endpoints 
than pre-exposure to NB followed by PhIP.  We also studied the activity of ECG and EGCG, at 
non-cytotoxic levels, in suppression of NBP-induced endpoints.  We determined that a 
combination of ECG and EGCG was more effective than either agent alone, at equivalent doses, 
in intervention of NBP-induced cellular carcinogenesis. 
 
Materials and Methods 
Cell cultures and reagents 
 MCF10A (American Type Culture Collection [ATCC], Rockville, MD) and derived cell 
lines were maintained in complete (CM) medium (1:1 mixture of DMEM and HAM's F12, 
supplemented with 100 ng/mL cholera enterotoxin, 10 µg/mL insulin, 0.5 µg/mL hydrocortisol, 
20 ng/mL epidermal growth factor, and 5% horse serum) [29–36].  Human breast cancer MCF7 
cells (ATCC) were maintained in DMEM supplemented with 10% heat-inactivated fetal calf 
serum [34,35].  All cultures were supplemented with 100 U/mL penicillin and 100 µg/mL 
streptomycin and maintained in 5% CO2 at 37°C.  Stock solutions of NNK (Chemsyn, Lenexa, 
KS), B[α]P (Aldrich, Milwaukee, WI), PhIP (Midwest; NCI Chemical Carcinogen Reference 
Standard Repository), U0126 (Cell Signaling, Beverly, MA), and CM-H2DCF-DA (Invitrogen, 
Carlsbad, CA) were prepared in DMSO; ECG, EGCG (Sigma-Aldrich, St. Louis, MO), and N-
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acetyl-L-cysteine (NAC) (Alexis, San Diego, CA) were prepared in distilled water.  All were 
diluted in CM medium for assays. 
 
Chronic induction of cellular carcinogenesis 
 Twenty-four hours after each subculturing, human breast cells were treated with the 
indicated carcinogens for 48 h as one cycle of exposure for 20 cycles. Cells were subcultured 
every 3 days [29–36].  
 
DNA Damage Assay 
 DNA damage was detected with a comet assay [38]. Cells were trypsinized and collected 
in phosphate-buffered saline (PBS) at a density of 2 × 104 cells/ml. Cell suspension was mixed 
with an equal volume of 1% low-melting agarose (Fisher, Fair Lawn, NJ) and placed on agarose-
coated slides. Slides were then immersed in lysis solution (1.2 mol/l NaCl, 100 mmol/l Na2-
EDTA, 1% Triton X-100 and 0.3 nmol/l NaOH, pH 13) at 25º C for 1 h and rinsed three times 
with alkaline buffer (2 mmol/l Na2-EDTA and 300 mmol/l NaOH) for 20 min each. After 
electrophoresis in the same alkaline buffer at 20 V for 30 min, slides were stained with 2.5 µg/ml 
of propidium iodide for 20 min and examined with a Zeiss fluorescence microscope (Carl Zeiss 
Inc, Thornwood, NY) equipped with an excitation filter of 546 nm and barrier filter of 590 nm. 
Fifty nuclei per slide were scored for tail moment (% of DNA in the tail × tail length) as a 





Reduced dependence on growth factors 
A total of 5 × 10
3
 cells were seeded in 60-mm culture dishes and maintained in low-
mitogen (LM) medium (1:1 mixture of DMEM/F12, 2 ng/mL cholera enterotoxin, 200 ng/mL 
insulin, 10 ng/mL hydrocortisol, 0.4 ng/mL epidermal growth factor, and 0.1% horse serum), 
containing reduced total serum and mitogenic additives to 2% of the concentration formulated in 
CM medium, for 10 days to develop cell colonies [32–35].  
 
Anchorage-independent growth 
A total of 1 × 10
4
 cells were mixed with soft agar consisting of 0.4% low-melting agarose 
(Sigma-Aldrich, St. Louis, MO) in a mixture (1:1) of CM medium with 3-day conditioned 
medium prepared from MCF10A cultures, plated on top of a 2% low-melting agarose base layer 
in 60-mm culture dishes and maintained for 14 days to develop cell clones [32–35].  
 
Measurement of intracellular ROS 
 Cultures were labeled with 5 µmol/L CM-H2DCF-DA for 1 h. Cells were trypsinized and 
resuspended in PBS for analysis of reactive oxygen species (ROS) by flow cytometry, using a 
15 mW, air-cooled argon laser to produce 488 nm light. DCF fluorescence emission was 
collected with a 529 nm band pass filter. The mean fluorescence intensity of 2 × 10
4
 cells was 





Cellular proliferation assay 
 Cell proliferation was determined using the 5-bromo-2-deoxyuridine (BrdU) cell 
proliferation enzyme-linked immunosorbent assay (ELISA) kit (Roche, Indianapolis, IN). A total 
of 5 × 10
3
 cells/well in 96-well culture plates were labeled with BrdU for 12 h, fixed, incubated 
with peroxidase-conjugated BrdU-specific antibodies and stained with the peroxidase substrate. 




Total RNA isolated from cultures using the Absolutely RNA kit (Stratagene, La Jolla, 
CA) was reverse transcribed to complementary DNA using the Verso cDNA Kit (Thermo 
Scientific, Waltham, MA). The resulting cDNAs were subjected to PCR for H-Ras (forward: 5’-
GACGGAAT ATAAGC TGGTGG-3’; reverse: 5’-AGGCACGTCTCCCCATCAAT-3’) and β-
actin (forward: 5’-GGACTTCGAGCAAGAGATGG-3’; reverse: 5’-AGCACTGTGTTGGCGT 




 Cell lysates were prepared in buffer (10 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100, 
5 mM EDTA, 10 mM sodium pyrophosphate, 10% glycerol, 0.1% Na3VO4, 50 mM NaF, pH 
7.4) [31,32]. Protein concentration in cell lysates was measured using the BCA assay (Pierce, 
Rockford, IL). Equal amounts of cellular proteins were resolved by electrophoresis in 10% or 
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12% sodium dodecyl sulfate-polyacrylamide gels for Western immunoblotting using specific 
antibodies to detect H-Ras, phosphorylated Erk1/2 (p-Erk1/2), Erk1/2, Nox-1, EpCAM, E-
cadherin, MMP-9, Vimentin, and β-actin (Santa Cruz Biotechnology, Santa Cruz, CA).  Antigen-
antibody complexes on filters were detected by the Supersignal chemiluminescence kit (Pierce, 
Rockford, IL).  
 
Serum-independent non-adherent growth 
A total of 1 × 10
4
 cells were seeded on top of 1% agarose-coated, non-adherent 100-mm 
culture plates, incubated in serum-free CM medium supplemented with 0.4% bovine serum 
albumin and maintained for 10 days to develop mammospheres [35,36].  
 
Aldehyde dehydrogenase (ALDH) assay 
An ALDEFLUOR Kit (StemCell Technologies, Durham, NC) was used to detect ALDH-
expressing cells [35,36]. A total of 1 × 10
5
 cells/ml were resuspended in assay buffer, mixed with 
activated Aldefluor substrate BAAA (BODIPY-aminoacetaldehyde), and incubated in the 
presence and absence of the ALDH inhibitor diethylaminobenzaldehyde (DEAB) at 37º C for 40 
min. Then, cells were resuspended in assay buffer for flow cytometric analysis by using a 15 
mW air-cooled argon laser to produce 488 nm light. Fluorescence emission was collected with a 
529-nm band pass filter. The mean fluorescence intensity of cells was quantified using 
Multicycle software (Phoenix Flow System, San Diego, CA). Cells incubated with BAAA in the 
presence of DEAB were used to establish the baseline of fluorescence for determining the 
ALDH-expressing cell population (%) in which ALDH activity was not inhibited by DEAB. 
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In vitro cell invasion and migration 
The in vitro cell invasion assay was performed using 24-well Transwell insert chambers 
with a polycarbonate filter with a pore size of 8.0 µm (Costar, Corning, NY).  A total of 2 × 10
4 
cells in serum-free medium were seeded on top of a Matrigel-coated filter (BD Biosciences, 
Franklin Lakes, NJ) in each insert chamber. Then, insert chambers were placed into wells on top 
of culture medium containing 10% horse serum as a chemoattractant. After 24 h, the invasive 
ability of cells was determined by the number of cells translocated to the lower side of filters 
[33–36]. 
The in vitro migration assay was performed using 24-well Transwell insert chambers 
with a polycarbonate filter not coated in Matrigel. The migration ability of cells was determined 
by the number of cells translocated to the lower side from the upper side of filters [33–36]. 
 
Cell motility wound-healing assay 
Cells were seeded in 6-well plates and grown to confluence in CM medium. Cells were 
rinsed with PBS and serum-starved for 15 h in DMEM/Ham’s F12 medium containing 2% horse 
serum. The monolayer was then scratched with a 23-gauge needle (BD Biosciences, Franklin 
Lakes, NJ) to generate wounds, rinsed with CM medium to remove floating cells, and then 
maintained in CM medium. The wounded areas were examined 6, 12 and 24 h after scratches to 
detect healing. The area not healed by the cells was subtracted from the total area of the initial 
wound to calculate the wound healing area at time intervals of 6 and 12 h, using Total Lab 





The Student t test was used to analyze statistical significance, indicated by * P<0.05, ** 
P<0.01, and *** P<0.001; a P value <0.05 was considered significant. 
 
Results and Discussion 
Enhanced cellular acquisition of cancer-associated properties by combined carcinogens  
 Previous studies have shown that NNK and B[α]P exhibit comparable abilities to induce 
breast cell carcinogenesis [33,34]. Combining NNK and B[α]P (NB) additively increased 
degrees of all acquired constitutive cellular endpoints except tumorigenicity [33,34], indicating 
that NNK and B[α]P may act as weak breast carcinogens. To detect whether NB could enhance 
breast cell carcinogenesis induced by the potent breast carcinogen PhIP, we first used a comet 
assay to measure the ability of these carcinogens to induce cellular DNA damage after one 
exposure, which is essential for the induction of cellular carcinogenesis [37]. Exposure to 
combined NB and PhIP (NBP) induced a significantly higher level of DNA damage than either 
NB or PhIP (Figure 2.1A). Blockage of the ERK pathway (with the Mek-specific inhibitor 
U0126) or ROS production (with the general antioxidant NAC) significantly reduced NB-, PhIP-
, and NBP-induced DNA damage (Figure 2.1A). These results indicate that co-exposure to NB 
and PhIP was more potent than either was alone to induce DNA damage for induction of cellular 
carcinogenesis, and the ERK pathway and ROS production are required for this process.   
 To verify whether cumulative exposures to NB and PhIP would result in enhanced 
cellular carcinogenesis, we exposed MCF10A cells to NB, PhIP, and NBP for 20 cycles, 
resulting in the NB20, P20, and NBP20 cell lines, respectively. NB20 cells were then exposed to 
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PhIP for an additional 20 cycles, resulting in the NB20/P20 cell line. We then compared the 
potency of these resulting cell lines by measuring degrees of acquired cancer-associated 
properties/constitutive endpoints [29–35]. Growth factors and cellular adhesion to the 
extracellular matrix are required for normal epithelial cell survival; in contrast, cancerous cells 
acquire a reduced dependence on growth factors (RDGF) and anchorage-independent growth 
(AIG) to increase survivability [37]. Increased ROS production and cellular proliferation are also 
closely associated with cellular transformation [37]. We detected that NB20/P20 and NBP20 
cells acquired higher degrees of RDGF (Figure 2.1B-1), AIG (2.1B-2), ROS content (2.1B-3), 
and cellular proliferation (2.1B-4) than NB20 or P20 cells. NBP20 cells acquired higher degrees 
of these endpoints than NB20/P20 cells, reaching levels comparable to malignant control 
MCF10A-Ras cells, in which oncogenic H-Ras is ectopically expressed in MCF10A cells [39]. 
The results indicate that pre-exposure (NB20/P20) or co-exposure (NBP20) to NB significantly 
enhanced PhIP-induced constitutive endpoints, with co-exposure being the most potent.  
 Our previous studies showed that up-regulated H-Ras gene expression, as a constitutive 
molecular endpoint, and activated Ras-ERK-Nox pathway, as a constitutive biochemical 
endpoint, are essential for maintaining constitutive cellular endpoints induced by PhIP [35]. In 
studying if these molecular and biochemical changes were enhanced by NBP, we detected that 
cumulative pre- and co-exposures to NB and PhIP resulted in highly up-regulated H-Ras gene 
expression (Figure 2.1B-5), increased H-Ras protein level, and activated downstream ERK-Nox 
pathway (2.1B-6) in NB20/P20 and NBP20 cells; these endpoints were up-regulated to higher 
levels in NBP20 cells than in NB20/P20 cells but did not reach their counterpart levels in 
MCF10A-Ras cells.  These results indicate that NNK and B[α]P can enhance the ability of PhIP 
to induce breast epithelial cell carcinogenesis, even though NNK is not considered a mammary 
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carcinogen, and B[α]P is considered a weak mammary carcinogen. Co-exposure to these 
carcinogens is more potent than pre-exposure to induce cellular acquisition of cancer-associated 
properties. The constitutive biochemical endpoints of Ras-ERK-Nox pathway activation and 
ROS elevation were induced consistently with constitutive cellular endpoints and may play 
important roles in maintaining cancer-associated properties in NBP-exposed cells.   
 To verify roles the ERK pathway and ROS may play in NBP-exposed cells, we used 
U0126 to inhibit Mek and NAC to inhibit ROS in NB20/P20 and NBP20 cells. Treatment with 
U0126 did not affect H-Ras expression but reduced Erk1/2 activity, Nox-1 expression (Figure 
2.1C-1), ROS level (2.1C-2), and cell proliferation (2.1C-3), indicating that the ERK-Nox 
pathway plays an important role in maintaining ROS production and cell proliferation in both 
NB20/P20 and NBP20 cells. NAC treatment suppressed the Ras-ERK-Nox pathway (Figure 
2.1C-1), ROS level (2.1C-2), and cell proliferation (2.1C-3), indicating an essential role for ROS 
production in maintaining activated Ras-ERK-Nox pathway and increased cell proliferation. 
These results reveal a cross-talk between the Ras-ERK-Nox pathway and ROS production, 
which are necessary for maintaining increased cell proliferation, and possibly other cancer-
associated properties, in NBP-exposed cells.   
 
Enhanced acquisition of stem-like and mesenchymal cell properties by combined 
carcinogens  
 Mammary stem-like cells are able to self-renew in serum-free media, are known to 
exhibit high levels of ALDH activity, and have a unique ability to form discrete spheroid clusters 
called mammospheres in non-adherent cultures [40,41]. We have reported that enrichment of 
ALDH-positive cell populations and increased formation of mammospheres were induced by 
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cumulative exposures to NB [36] or PhIP [35] in MCF10A cells. However, increased stem-like 
cell population is not yet fully appreciated as a breast cancer-associated property. Growth of 
mammospheres (serum-independent non-adherent growth, SINAG) involves the properties of 
RDGF and AIG, both of which are enhanced by NBP exposure. Thus, it was important to 
understand whether NBP-enhanced cellular carcinogenesis was accompanied by enhanced stem-
like cell properties.  As shown in Figure 2.2, mammospheres (2.2A) and ALDH-positive cell 
population (2.2B) were increasingly induced in NB20, P20, NB20/P20, and NBP20 cells (NB20 
< P20 < NB20/P20 < NBP20). Accordingly, cumulative co-exposures of cells to NBP resulted in 
acquisition of significantly increased stem-like cell populations that should be considered a novel 
cancer-associated property used to measure the progression of breast cell carcinogenesis.   
 The ability to develop stem-like cells is associated with activation of the EMT program 
[37]. During EMT, reduction of epithelial cellular adhesion molecule (EpCAM) and E-cadherin 
is associated with a loss in cell-cell adhesion [42] while an increase in matrix metalloproteinase-
9 (MMP-9) is involved in degradation of the extracellular matrix [37]; increased Vimentin plays 
a role in filament formation and cell motility [43]. We detected that EpCAM and E-cadherin 
were reduced but MMP-9 and Vimentin were increased (Figure 2.2C) in NB- and/or PhIP-
exposed cells, and these changes occurred consistently with degrees of increased mammosphere 
formation (2.2A) and enriched ALDH-positive stem-like cell populations (2.2B). Induction of 
the EMT program has been postulated to not only contribute to cellular acquisition of stem-like 
properties but also increased migratory and invasive capabilities [37]. We detected that increased 
degrees of cell migration (Figure 2.2D) and invasion (2.2E) were closely correlated with the 
increased degrees of mammosphere formation (2.2A), stem-like cell population (2.2B), and EMT 
markers (2.2C) acquired by NB- and/or PhIP-exposed cells: NBP20 > NB20/P20 > P20 > NB20.  
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In addition, using a wound healing assay, we detected that increased cell motility (Figure 2.2F-1 
and 2.2F-2) was also accordingly acquired by these NB- and/or PhIP-exposed cells. These results 
indicate that cumulative exposure to NBP significantly enhanced cellular acquisition of stem-like 
and EMT-associated markers and properties. Cellular acquisition of stem-like and EMT-
associated properties should be considered as novel cancer-associated properties and constitutive 
endpoints in measurement of the progression of breast cell carcinogenesis.  
 
NBP enhanced cancer-associated properties in breast cancer MCF7 cells  
 To clarify whether the enhanced acquisition of cancer-associated properties induced by 
NBP was limited to MCF10A cells, we exposed human breast cancer MCF7 cells to NBP, NB, 
and PhIP. A single exposure to NBP induced more DNA damage in MCF7 cells than either NB 
or PhIP (Figure 2.3A) indicating that NBP is more potent than either NB or PhIP alone to induce 
DNA damage for cellular carcinogenesis, even in cancer cells. After five cycles of carcinogen 
exposure, we detected significantly increased degrees of the cancer-associated properties of 
RDGF (Figure 2.3B-1), AIG (2.3B-2), cell migration (2.3B-3), and invasion (2.3B-4) acquired 
by carcinogen-exposed MCF7 cells versus parental cells. Although parental MCF7 cells 
possessed levels of these cancer-associated properties comparable to levels in NBP20 and 
MCF10A-Ras cells, these properties were significantly increased by NBP exposure, indicating 
that cumulative exposures to NBP may increase the potency of already cancerous cells. NBP was 
more potent than NB or PhIP in MCF7 cells, which is consistent with results seen in MCF10A 
cells. We next investigated if cumulative exposures to NBP, NB, and PhIP also resulted in 
induction of the biochemical endpoints of ROS elevation and Ras-ERK-Nox pathway activation 
in MCF7 cells as they did in MCF10A cells. We detected that parental MCF7 cells possessed 
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higher levels of ROS (Figure 2.3B-5), H-Ras expression, Erk1/2 activation, and Nox-1 
expression (2.3B-6) than MCF10A cells, and cumulative exposures to NBP were able to 
furthermore increase ROS production and Ras-ERK-Nox pathway induction in MCF7 cells. 
Exposure to NBP resulted in higher levels of ROS production (Figure 2.3B-5) and Ras-ERK-
Nox pathway induction (2.3B-6) in MCF7 cells than either NB or PhIP alone, consistent with the 
higher levels of cancer-associated properties (2.3B-1 to 2.3B-4) acquired by NBP-exposed 
versus NB- or PhIP-exposed MCF7 cells.  Thus, these results lead us to suggest that cumulative 
exposures to combined NNK, B[α]P, and PhIP were able to constitutively induce cellular 
acquisition of cancer-associated properties and associated biochemical endpoints in not only 
non-cancerous MCF10A cells, but also in cancerous MCF7 cells in a similar manner. A 
combination of multiple carcinogens was more potent than individual carcinogens in long-term 
induction of breast cell carcinogenesis. Thus, co-exposure to low doses of NNK, B[α]P, and 
PhIP should be seriously considered in epidemiological studies to reveal the value of these 
carcinogens in the development of sporadic breast cancer. Given their ability to increase cancer-
associated properties in non-cancerous or cancerous cells alike, it is important to identify dietary 
agents capable of blocking breast cell carcinogenesis induced by cumulative exposures to 
combined carcinogens for early intervention of this disease.  
 
Intervention of NBP-induced carcinogenesis 
 In our previous reports, we demonstrated that GTCs, at non-cytotoxic levels, were 
capable of suppressing breast cell carcinogenesis induced by NB or PhIP [33–35]. EGCG, the 
major catechin present in green tea extract, is the most commonly studied preventive GTC [44], 
but some studies have shown that ECG may be more effective than EGCG in intervention of 
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cellular carcinogenesis [34,45,46].  ECG and EGCG have similar molecular masses, 442.37 and 
458.37 g/mol, respectively. Our previous studies revealed that both ECG and EGCG at 40 µg/mL 
are toxic to MCF10A cells [34]. However, at a non-cytotoxic dose of 10 µg/mL, ECG is more 
effective than EGCG in suppression of NB-induced cellular carcinogenesis [34]. ECG at 10 
µg/mL and EGCG at 5 µg/mL show comparable effectiveness in suppression of PhIP-induced 
cellular carcinogenesis [35]. Thus, to address whether ECG, EGCG, or a combination of both 
would be most effective in suppressing NBP-induced cellular carcinogenesis, we initially studied 
the effectiveness of ECG and EGCG, at non-cytotoxic doses, in blocking transient endpoints 
induced by a single exposure to NBP and subsequently verified their ability to suppress NBP-
induced constitutive endpoints after cumulative exposures.    
 As shown in Figure 2.4, both ECG (E) and EGCG (G), at 10 or 20 µg/mL, were able to 
block NBP-induced transient endpoints of ROS elevation (2.4A-1) and DNA damage (2.4A-2), 
with ECG being more effective than EGCG in suppressing these properties. Interestingly, a 
combination of ECG and EGCG (E+G) at 5 or 10 µg/mL each was more effective than 
individual catechins at 10 or 20 µg/mL, respectively, in suppression of NBP-induced ROS and 
DNA damage, indicating that combined ECG and EGCG were optimal for blocking ROS 
elevation and DNA damage induced by combined NNK, B[α]P, and PhIP. Consistently, ECG 
was more effective than EGCG, and a combination of ECG and EGCG was more effective than 
individual catechins in suppression of Ras expression, Erk1/2 activity, and Nox-1 expression 
(Figure 2.4A-3), as well as cellular proliferation (2.4A-4) transiently induced by a single 
exposure to NBP. These results indicate that a combination of ECG and EGCG, at non-cytotoxic 
levels, was more effective than individual agents in blocking induction of breast cell 
carcinogenesis by NBP.   
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 To verify the ability of ECG and EGCG to intervene with the progression of NBP-
induced cellular carcinogenesis, we repeatedly exposed MCF10A cells to NBP in the absence or 
presence of 20 µg/mL ECG (E), 20 µg/mL EGCG (G), or combined 10 µg/mL ECG and 10 
µg/mL EGCG (E/G) for 10 cycles, resulting in the NBP10, NBP-E10, NBP-G10, and NBP-
E/G10 cell lines, respectively. In studies of the ability of ECG and/or EGCG to block NBP-
induced cancer-associated properties, we detected that ECG was more effective than EGCG and 
a combination of ECG and EGCG was more effective than individual catechins in intervention of 
cellular acquisition of RDGF (Figure 2.4B-1), AIG (2.4B-2), increased cell migration (2.4B-3), 
invasion (2.4B-4), and proliferation (2.4B-5), as well as ROS elevation (2.4B-6) and Ras-ERK-
Nox pathway activation (2.4B-7). Furthermore, NBP-increased mammosphere formation (Figure 
2.4B-8) and ALDH-positive stem-like cell population (2.4B-9) as well as EMT-associated 
MMP-9 induction, Vimentin induction, EpCAM reduction, and E-cadherin reduction (2.4B-10) 
were also blocked by co-exposure to ECG and EGCG. Consistently, ECG was more effective 
than EGCG, and a combination of ECG and EGCG was more effective than individual catechins 
in suppressing these properties. These results clearly indicate the effectiveness of ECG and 
EGCG, at non-cytotoxic levels, in intervention of breast cell carcinogenesis associated with long-
term exposure to NBP. A combination of ECG and EGCG was more effective than either agent 
alone, at equivalent doses in intervention of NBP-induced breast cell carcinogenesis.  
 Our unique model presents several advantages over others to advance our understanding 
of human breast carcinogenesis and early intervention. It is highly sensitive in detecting 
physiologically-achievable, low doses of either weak or potent carcinogens capable of inducing 
breast cell carcinogenesis. It takes a unique approach of exposing cells to carcinogens in a 
cumulative manner for progressive induction of chronic carcinogenesis from non-cancerous to 
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pre-cancerous and cancerous stages. In addition, it uses measurable transient and constitutive 
cellular, biochemical, and molecular endpoints to determine the induction and progression of 
cellular carcinogenesis and to identify non-cytotoxic agents effective in intervention. In this 
communication, we used our model to demonstrate, for the first time, the ability of two relatively 
weak breast carcinogens, NNK and B[α]P, to enhance breast cell carcinogenesis induced by 
potent breast carcinogen PhIP; we also identified the ability of combined ECG and EGCG, 
which was more effective than individual catechins, to intervene in carcinogenesis induced by 
combined NNK, B[α]P, and PhIP. We reported that transient induction of ROS, the Ras-ERK-
Nox pathway, cell proliferation, and DNA damage accounted for the mechanisms of initiation of 
cellular carcinogenesis during each exposure to NNK, B[α]P, and/or PhIP [34,35], ultimately 
leading to acquisition of cancer-associated properties and progression of cellular carcinogenesis 
induced by cumulative exposures. These transient endpoints were highly enhanced by combined 
NNK, B[α]P, and PhIP. Blockage of ROS elevation or the Ras-ERK-Nox pathway significantly 
reduced NBP-induced DNA damage and cell proliferation, indicating essential roles of ROS 
elevation and Ras-ERK-Nox pathway activation in NBP-induced cellular carcinogenesis. 
Accordingly, transient induction of ROS elevation and the Ras-ERK-Nox pathway served not 
only as markers for detecting NBP effects but also as targets for suppressing NBP-induced 
carcinogenesis. As we demonstrated in this communication, we initially used ROS elevation and 
the Ras-ERK-Nox pathway as targets to detect the optimal concentration and combination of 
ECG and EGCG effective in suppression of NBP-induced transient endpoints. Subsequently, we 
used cancer-associated properties/constitutive endpoints as targets to verify the effectiveness of 
combined ECG and EGCG in intervention of NBP-induced progression of cellular 
carcinogenesis. In addition, our model system is able to address whether preventive agents are 
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effective in intervention of cancer stem-like cell development. Development of cancer stem-like 
cells, involving induction of the EMT program, has been postulated to play important roles in 
cancer development [37] and cancer recurrence after chemotherapy [47]. Using our model, we 
demonstrated that combined ECG and EGCG was more effective than individual agents in 
intervention of NBP-increased stem-like cell population and EMT program induction. Thus, 
applying our model will accelerate our understanding of low-dose carcinogens in breast cell 
carcinogenesis and identification of preventive agents effective in reducing the health risk of 
sporadic breast cancer associated with chronic exposure to low doses of environmental and 
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Figure 2.1. Enhanced cellular acquisition of cancer-associated properties by combined 
carcinogens. (A) MCF10A cells were treated with combined 100 pmol/L NNK and 100 pmol/L 
B[α]P (NB), 10 nmol/L PhIP (P), or combined NB and PhIP (NBP) in the absence and presence 
of 10 µmol/L U0126 (U0) or 5 mmol/L NAC for 24 h. DNA damage was measured by a comet 
assay and normalized by the value of average tail moment determined in untreated counterpart 
cells, set as 1 (X, arbitrary unit). Representative images detected in the comet assay are shown.  
(B-1 to B-6) MCF10A (10A) cells were repeatedly exposed to NB, PhIP, or NBP for 20 cycles, 
resulting in the NB20, P20, and NBP20 cell lines, respectively. NB20 cells were then exposed to 
PhIP for an additional 20 cycles resulting in the NB20/P20 cell line. MCF10A-Ras (Ras) cells 
were used as a malignant control. (C-1 to C-3) NB20/P20 and NBP20 cells were treated with 10 
µmol/L U0 or 5 mmol/L NAC for 48 h. (B-1) To determine cellular acquisition of RDGF, cells 
were maintained in LM medium for 10 days. Cell colonies ≥0.5 mm diameter were counted. (B-
2) To determine cellular acquisition of AIG, cells were seeded in soft agar for 14 days. Cell 
colonies ≥0.1 mm diameter were counted. (B-3 and C-2) Relative level of ROS as fold induction 
(X, arbitrary unit) was normalized by the level determined in untreated cells, set as 1. (B-4 and 
C-3) Relative cell proliferation was determined and normalized by the value of BrdU detected in 
untreated cells, set as 100%. B-5: Total RNA was isolated and analyzed by RT-PCR with 
specific primers to determine relative gene expression levels of H-Ras, with β-actin as a control, 
and these levels were quantified by densitometry. (B-6 and C-1) Cell lysates were analyzed by 
immunoblotting using specific antibodies to detect levels of H-Ras, phosphorylated-Erk1/2 (p-
Erk1/2), Erk1/2, and Nox-1, with β-actin as a control, and these levels were quantified by 
densitometry. The levels of H-Ras (Ras/actin) and Nox-1 (Nox/actin) were calculated by 
normalizing with the level of β-actin and the level set in untreated control cells as 1 (X, arbitrary 
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unit). Levels of specific phosphorylation of Erk1/2 (p/Erk) were calculated by normalizing the 
levels of p-Erk1/2 with the levels of Erk1/2, then the level set in control cells as 1 (X, arbitrary 
unit). Columns, mean of triplicates; bars, SD. All results are representative of three independent 
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Figure 2.2. Enhanced acquisition of mesenchymal and stem-like cell properties by 
combined carcinogens. (A) To determine cellular acquisition of the ability of serum-
independent non-adherent growth (SINAG), MCF10A (10A), NB20, P20, NB20/P20, NBP20, 
and MCF10A-Ras (Ras) cells were seeded in non-adherent cultures for 10 days; then, 
mammospheres (≥0.1 mm diameter) were counted. (B) Mammospheres were collected and 
trypsinized, and ALDH-expressing (ALDH
+
) cell population (%) was measured by flow 
cytometry. (C) Cell lysates were analyzed by immunoblotting using specific antibodies to detect 
levels of EpCAM, E-cadherin, MMP-9 and Vimentin, with β-actin as a control, and these levels 
were quantified by densitometry. The levels of EpCAM, E-cadherin, MMP-9, and Vimentin 
were calculated by normalizing with the level of β-actin and the level set in untreated control 
cells as 1 (X, arbitrary unit). (D) Cellular migratory and E: invasive activities were determined 
by counting the numbers of cells translocated through a polycarbonate filter without or with 
coated Matrigel, respectively, in 10 arbitrary visual fields. (F-1) Cellular acquisition of increased 
motility was determined by wound healing assay.  The wounded areas were examined 
(magnification, 100×) 6, 12, and 24 h afterward.  Arrows indicate width of wounded areas. (F-2) 
To quantitatively measure cell motility detected in F-1, the area not healed by the cells was 
subtracted from the total area of the initial wound to calculate the wound healing area (%) at 
intervals of 6 (white columns) and 12 h (gray columns). Columns, mean of triplicates; bars, SD.  
All results are representative of three independent experiments. Statistical significance is 




















Figure 2.3. NBP-enhanced cancer-associated properties in breast cancer MCF7 cells. (A) 
MCF10A cells (10A) were treated with NBP, and MCF7 cells were treated with NBP, NB, or 
PhIP (P) for 24 h.  DNA damage was measured by a comet assay and normalized by the value of 
average tail moment determined in untreated counterpart cells, set as 1 (X, arbitrary unit). (B-1 to 
B-6) MCF7 cells were exposed to NBP, NB, or PhIP for five cycles (NBP5, NB5, and P5). The 
NBP20 and MCF10A-Ras (Ras) cell lines were used as comparisons. (B-1) To determine cellular 
acquisition of RDGF, cells were maintained in LM medium for 10 days. Cell colonies ≥0.5 mm 
diameter were counted. (B-2) To determine cellular acquisition of AIG, cells were seeded in soft 
agar for 14 days. Cell colonies ≥0.1 mm diameter were counted. Cellular migratory (B-3) and 
invasive (B-4) activities were determined by counting the numbers of cells translocated through 
a polycarbonate filter without or with coated Matrigel, respectively, in 10 arbitrary visual fields.  
(B-5) Relative level of ROS as fold induction (X, arbitrary unit) was normalized by the level 
determined in untreated cells, set as 1. (B-6) Cell lysates were analyzed by immunoblotting using 
specific antibodies to detect levels of H-Ras, p-Erk1/2, Erk1/2, and Nox-1, with β-actin as a 
control, and these levels were quantified by densitometry. Levels of H-Ras (Ras/actin) and Nox-
1 (Nox/actin) were calculated by normalizing with the level of β-actin and the level set in 
untreated control cells as 1 (X, arbitrary unit). Levels of specific phosphorylation of Erk1/2 
(p/Erk) were calculated by normalizing the levels of p-Erk1/2 with the levels of Erk1/2, then the 
level set in control cells as 1 (X, arbitrary unit). Columns, mean of triplicates; bars, SD. All 
results are representative of three independent experiments. Statistical significance is indicated 
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Figure 2.4. Intervention of NBP-induced carcinogenesis. (A-1 to A-4) MCF10A cells were 
treated with NBP in the absence and presence of ECG (E), EGCG (G), or a combination of ECG 
and EGCG (E+G) for 24 hr. (B-1 to B-10) MCF10A (10A) cells were exposed to NBP in the 
absence and presence of 20 µg/mL ECG, 20 µg/mL EGCG, or combined 10 µg/mL ECG and 10 
µg/mL EGCG (E/G) for 10 cycles, resulting in the NBP10, NBP-E10, NBP-G10, and NBP-
E/G10 cell lines, respectively. (A-1 and B-6) Relative level of ROS as fold induction (X, 
arbitrary unit) was normalized by the level determined in untreated cells, set as 1. (A-2) Relative 
DNA damage was measured by a comet assay and normalized by the value of average tail 
moment determined in untreated counterpart cells, set as 1 (X, arbitrary unit). (A-3 and B-7) Cell 
lysates were analyzed by immunoblotting using specific antibodies to detect levels of H-Ras, 
phosphorylated-Erk (p-Erk), Erk, and Nox-1, with β-actin as a control, and these levels were 
quantified by densitometry. Levels of H-Ras and Nox-1 were calculated by normalizing with the 
level of β-actin and the level set in untreated control cells as 1 (X, arbitrary unit). Levels of 
specific phosphorylation of Erk (p/Erk) were calculated by normalizing the levels of p-Erk with 
the levels of Erk, then the level set in control cells as 1 (X, arbitrary unit). (A-4 and B-5) Relative 
cell proliferation was determined and normalized by the value of BrdU detected in untreated 
cells, set as 100%. (B-1) To determine cellular acquisition of RDGF, cells were maintained in 
LM medium for 10 days. Cell colonies ≥0.5 mm diameter were counted. (B-2) To determine 
cellular acquisition of AIG, cells were seeded in soft agar for 14 days. Cell colonies ≥0.1 mm 
diameter were counted. (B-3) Cellular migratory and (B-4) invasive activities were determined 
by counting the numbers of cells translocated through a polycarbonate filter without or with 
coated Matrigel, respectively, in 10 arbitrary visual fields. (B-8) To determine cellular 
acquisition of the ability of serum-independent non-adherent growth (SINAG), cells were seeded 
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in non-adherent cultures for 10 days; then, mammospheres (≥0.1 mm diameter) were counted.  
(B-9) Mammospheres were collected and trypsinized, and ALDH-expressing (ALDH
+
) cell 
population (%) was measured by flow cytometry. (B-10) Cell lysates were analyzed by 
immunoblotting using specific antibodies to detect levels of EpCAM, E-cadherin, MMP-9 and 
Vimentin, with β-actin as a control, and these levels were quantified by densitometry. The levels 
of EpCAM, E-cadherin, MMP-9 and Vimentin were calculated by normalizing with the level of 
β-actin and the level set in untreated control cells as 1 (X, arbitrary unit). Columns, mean of 
triplicates; bars, SD.  All results are representative of three independent experiments. Statistical 
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Most breast cancers occur sporadically due to long-term exposure to low doses of 
carcinogens present in the polluted environment and diet. American lifestyles involve frequent 
exposures to smoke, polluted air and high temperature-cooked meats comprising multiple 
carcinogens, such as 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), benzo[α]pyrene 
(B[α]P), and  2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). However, whether 
these carcinogens may act together to enhance breast cell carcinogenesis is unclear. Here, we 
demonstrate that co-exposure to physiologically-achievable doses of NNK, B[α]P, and PhIP 
(NBP) holistically enhanced initiation and progression of breast cell carcinogenesis. Reactive 
oxygen species (ROS) and ERK pathway activation were transiently induced by each NBP 
exposure, and cross-talk between reinforced ROS elevation and ERK activation played an 
essential role in increased DNA oxidation and damage. After cumulative NBP exposures, this 
cross-talk contributed to enhanced initiation of cellular carcinogenesis and led to enhanced 
acquisition of cancer-associated properties. Using NBP-induced transient changes, such as ROS 
elevation and ERK pathway activation, and cancer-associated properties as targeted endpoints, 
we revealed, for the first time, that two less-studied dietary compounds, ergosterol and 
mimosine, at biologically-achievable non-cytotoxic levels, were highly effective in suppressing 
NBP-induced cellular carcinogenesis. Combined ergosterol and mimosine was more effective 
than individual agents in blocking NBP-induced transient endpoints, including ROS-mediated 
DNA oxidation, which accounted for its ability to suppress progression of NBP-induced cellular 
carcinogenesis. Thus, dietary components such as mushrooms containing ergosterol and legumes 
containing mimosine should be considered for affordable prevention of sporadic breast cancer 




Breast cancer is the most common type of cancer and second-leading cause of cancer-
related death among North American and European women [1].  Most breast cancers occur 
sporadically due to chronic exposure to multiple environmental carcinogens in a multi-step 
process that results in the transformation of breast cells from a non-cancerous stage to pre-
cancerous and cancerous stages [2,3].  We have developed a chronically-induced breast cell 
carcinogenesis model to mimic sporadic breast cancer development associated with long-term 
exposure to low doses of carcinogens [4-9].  In this model, we repeatedly expose immortalized, 
non-cancerous, human breast epithelial cells to physiologically-achievable doses of carcinogens 
to progressively induce cellular acquisition of various cancer-associated properties for studies to 
reveal cellular, biochemical, and molecular changes.  Then, we use these changes as targeted 
endpoints to identify preventive agents capable of intervening in cellular carcinogenesis [4-9].   
 The mammary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) is 
the most abundant heterocyclic amine produced in high-temperature cooked meat, and 
circulating plasma levels of PhIP can reach nanomolar levels in humans following cooked meat 
consumption [10].  In rats, gastric administration of PhIP induces mammary tumors [11].  In 
addition, epidemiological studies have indicated a close association between well-done meat 
consumption and human breast cancer risk [12,13].  The tobacco-specific nitrosamine ketone 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is widely accepted as a lung carcinogen 
and can be detected at picomolar concentrations in the body fluids of tobacco users [14].  Despite 
evidence that gastric administration into rats resulted in mammary tumor development [15], 
NNK is not recognized as a mammary carcinogen.  Although the link between smoking and 
breast cancer is controversial, recent studies have indicated that exposure to tobacco smoke can 
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increase breast cancer risk, especially in post-menopausal women [16,17].  Benzo[α]pyrene 
(B[α]P) is a polycyclic aromatic hydrocarbon in smoke produced from the incomplete 
combustion of organic materials, such as fossil fuels and tobacco [18].  B[α]P can be found at 
picomolar concentrations in human fat and liver [19] and is classified as a weak mammary 
carcinogen in humans [18,20,21].  American lifestyles involve frequent consumption of high-
temperature cooked meats containing carcinogens such as PhIP and wide exposures to smoke 
and polluted air containing NNK and B[α]P.  However, whether these carcinogens may act 
together to cause breast cell carcinogenesis needs to be verified.   
 Epidemiological and experimental evidence suggests that certain dietary compounds 
possess anticancer activities [3].  Ergosterol is a sterol that forms the major constituent of the 
fungal cell membrane [22].  Common dietary sources include mushrooms, morels, and truffles 
[22], as well as products made with yeasts such as soy sauce, bread, and beer [23-25].  Studies 
showed that ergosterol at micro-molar levels is cytotoxic against human breast cancer cell lines 
and a variety of other tumor cell lines [26,27].  In vivo studies identified ergosterol as a 
protective agent against the promotion of carcinogen-induced bladder tumors in rats [28] and 
tumor promotion in mice [29].  Mimosine is an alkaloid, non-proteinogenic amino acid found 
exclusively in tropical legumes of the Mimosa and Leucaena genera [30].  Mimosine is an iron 
chelator that inhibits DNA synthesis and causes cell cycle arrest in late G1 phase [30].  Studies 
showed that micro-molar levels of mimosine inhibit proliferation of breast, lung, and ovarian 
cancer cell lines [31-33], and mimosine is effective in reducing xenograft development of human 
lung and pancreatic carcinoma cells by increasing the apoptotic index of cancer cells [34,35].  
Although much research has focused on the use of high doses of ergosterol and mimosine to 
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inhibit growth or induce apoptosis of cancer cells, little work has been undertaken to evaluate the 
ability of these agents, at non-cytotoxic levels, to prevent cellular carcinogenesis.  
 Given the ubiquitous nature of tobacco smoke, carbon exhaust, and cooked meat in 
modern societies, it is important to holistically examine the role of carcinogens, such as NNK, 
B[α]P, and PhIP, in induction of breast cell carcinogenesis to reveal associated mechanisms and 
targeted endpoints for intervention.  Previously, we used our breast cell carcinogenesis model 
system to demonstrate the ability of NNK at100 pmol/L, B[α]P at 100 pmol/L, and PhIP at 10 
nmol/L to individually induce initiation and progression of breast cell carcinogenesis [4,5,9].  
NNK and B[α]P exhibited comparable abilities to induce cellular carcinogenesis, and combining 
NNK and B[α]P (NB) additively increased degrees of acquired cancer-associated properties, 
such as reduced dependence on growth factors and anchorage-independent growth, as well as 
stem-like cell- and epithelial-to-mesenchymal transition (EMT)-associated properties [6-9].  
These measurable cancer-associated properties, acquired by cells after cumulative exposures to 
carcinogens, represent constitutive endpoints to reveal stages in the progress of cellular 
carcinogenesis from non-cancerous to premalignant and malignant stages.  Using our model, we 
have also identified endpoints that are transiently induced by a single carcinogen exposure, such 
as DNA damage and increased cell proliferation, which play essential roles in induction of 
carcinogenesis and account for the mechanisms of initiation of cellular carcinogenesis during 
each carcinogen exposure [6,7,9].  Our model system enables us to develop a two-step strategy 
by also using these transient and constitutive endpoints as targets to identify preventive agents 
capable of blocking cellular carcinogenesis [5-9].   
 Herein, we describe use of our model system to elucidate the ability, and associated 
mechanisms, of NB to enhance PhIP-induced cellular carcinogenesis.  We also used our model 
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as a target system to demonstrate, for the first time, the ability, and associated mechanisms, of 
ergosterol and mimosine individually and in combination to suppress cellular carcinogenesis 
induced by combined NNK, B[α]P, and PhIP.   
 
Materials and Methods 
Cell cultures and reagents 
MCF10A, MCF12A (American Type Culture Collection [ATCC], Rockville, MD) and 
derived cell lines were maintained in complete medium (CM) (1:1 DMEM/HAM's F12, 100 
ng/mL cholera enterotoxin, 10 µg/mL insulin, 0.5 µg/mL hydrocortisol, 20 ng/mL epidermal 
growth factor, and 5% horse serum) [4-9].  All cultures were supplemented with 100 U/mL 
penicillin and 100 µg/mL streptomycin and maintained in 5% CO2 at 37°C.  Stock solutions of 
NNK (Chemsyn, Lenexa, KS), B[α]P (Aldrich, Milwaukee, WI), PhIP (Midwest; NCI Chemical 
Carcinogen Reference Standard Repository), U0126 (Cell Signaling, Beverly, MA), and CM-
H2DCF-DA (Invitrogen, Carlsbad, CA) were prepared in DMSO; ergosterol (Sigma-Aldrich, St. 
Louis, MO) was prepared in chloroform; N-acetyl-L-cysteine (NAC) (Alexis, San Diego, CA) 
was prepared in distilled water, and mimosine (Sigma-Aldrich) was prepared in distilled water 
with 10% NaOH.  All were diluted in CM for assays. 
 
Chronic induction of cellular carcinogenesis 
 Twenty-four hours after subculturing, human breast cells were treated with the indicated 
carcinogens and/or preventive agents for 48 h as one cycle of exposure for 5-20 cycles. Cells 




 A methyl thiazolyl tetrazolium (MTT) assay kit (ATCC) was used to measure cell 
viability. A total of 5×10
3
 cells/well in 96-well culture plates were incubated with MTT reagent 
for 4 h, followed by incubation with detergent reagent for 24 h. Reduced MTT reagent in 
cultures was quantified with an ELISA reader (Bio-Tek) at 570 nm. 
 
Reduced dependence on growth factors 
A total of 5×10
3
 cells were seeded in 60-mm culture dishes and maintained in low-
mitogen (LM) medium (1:1 DMEM/F12, 2 ng/mL cholera enterotoxin, 200 ng/mL insulin, 10 
ng/mL hydrocortisol, 0.4 ng/mL epidermal growth factor, and 0.1% horse serum), containing 
reduced total serum and mitogenic additives to 2% of the concentration formulated in CM, for 10 
days to develop cell colonies [4-9].  
 
Anchorage-independent growth 
A total of 1×10
4
 cells were mixed with soft agar consisting of 0.4% low-melting agarose 
(Fisher, Fair Lawn, NJ) in a mixture (1:1) of CM with 3-day conditioned medium prepared from 
MCF10A cultures, plated on top of a 2% low-melting agarose base layer in 60-mm culture dishes 







Cell proliferation was determined using the 5-bromo-2-deoxyuridine (BrdU) cell  
proliferation enzyme-linked immunosorbent assay (ELISA) kit (Roche, Indianapolis, IN); BrdU- 
labeled cells were quantified using an ELISA reader (Bio-Tek, Winooski, VT), as described 
previously [4-9]. 
 
Serum-independent non-adherent growth 
A total of 1×10
4
 cells were seeded on top of 1% agarose-coated, non-adherent 100-mm 
culture plates, incubated in serum-free CM supplemented with 0.4% bovine serum albumin and 
maintained for 10 days to develop mammospheres [8,9].  
 
Aldehyde dehydrogenase (ALDH) 
An ALDEFLUOR Kit (StemCell Technologies, Durham, NC) was used to detect ALDH-
expressing cells by flow cytometry, as described previously [8.9]. Mean fluorescence intensity of 
cells was quantified using Multicycle software (Phoenix Flow System). Cells incubated with 
activated Aldefluor substrate BODIPY-aminoacetaldehyde (BAAA) in the presence of the 
ALDH inhibitor diethylaminobenzaldehyde (DEAB) were used to establish the baseline of 
fluorescence for determining the ALDH-expressing cell population (%) in which ALDH activity 





In vitro cell invasion and migration  
The in vitro cell invasion assay was performed using 24-well transwell insert chambers 
with an 8.0 µm pore size polycarbonate filter (Costar, Corning, NY).  A total of 2×10
4
 cells in 
serum-free CM were seeded on top of a Matrigel-coated filter (BD Biosciences, Franklin Lakes, 
NJ) in each insert chamber. Insert chambers were then placed into wells on top of culture 
medium containing 10% horse serum as a chemoattractant. The in vitro migration assay was 
performed using 24-well Transwell insert chambers with a polycarbonate filter not coated in 
Matrigel. After 24 h, the migratory and invasive ability of cells was determined by the number of 
cells translocated to the lower side of filters [8,9]. 
 
Cell motility wound-healing 
Cells were seeded in 6-well plates, grown to confluence in CM, rinsed with PBS and 
serum-starved for 15 h in DMEM/Ham’s F12 medium containing 2% horse serum. The 
monolayer was scratched with a 23-gauge needle (BD Biosciences) to generate wounds, rinsed 
with CM to remove floating cells, and then maintained in CM. The wounded areas were 
examined 6, 12 and 24 h after scratches to detect healing. The area not healed by the cells was 
subtracted from the total initial wound area to calculate the wound healing area at time intervals 
of 6 and 12 h, using Total Lab TL100 software (Total Lab, Newcastle, NE) [7,8]. 
 
Intracellular ROS 
Cells were labeled with 5 µmol/L chloromethyl-dichlorodihydrofluorescein-diacetate 
(CM-H2DCF-DA) for 1 h to detect ROS by flow cytometry as described previously [4-9]. Mean 
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fluorescence intensity of dichlorodihydrofluorescein (DCF) was quantified using Multicycle 
software (Phoenix Flow System, San Diego, CA). 
 
DNA damage 
DNA damage was detected using the comet assay [38]. A total of 2×10
4
 cells in cold 
phosphate-buffered saline (PBS) were mixed with 1% low-melting agarose (Fisher) and placed 
on agarose-coated slides. Slides were immersed in alkaline lysis solution (pH 13) at 25º C for 1 
h, rinsed with alkaline buffer (pH>13), electrophoresed in the same buffer at 20 V for 30 min, 
stained with propidium iodide and examined with a fluorescence microscope (Carl Zeiss Inc., 
Thornwood, NY), as described previously [4-9].  Fifty nuclei per slide were scored for tail 
moment (% DNA in the tail × tail length) using CometScore software (Tritek, Sumerduck, VA).  
 
DNA oxidation 
DNA oxidation was detected using a modified comet assay [39].  In brief, after seeding 
cells onto agarose-coated slides, slides were immersed in neutral lysis solution (2.5 mol/L NaCl, 
0.1 mol/L Na2-EDTA and 10 mmol/L Tris, pH 8) and incubated with enzyme reaction buffer (40 
mmol/L HEPES, 0.1 mol/L KCl, 0.5 mmol/L Na2-EDTA and 0.2 mg/mL BSA, pH 8) buffer with 
and without formamidopyrimidine (fapy)-DNA glycosylase (Fpg) enzyme.  Slides were then 
placed in alkaline buffer, electrophoresed in alkaline buffer, rinsed with neutralization buffer (0.4 
mol/L Tris, pH 7.5), stained with propidium iodide, and examined with a fluorescence 





Total RNA isolated from cultures using the Absolutely RNA kit (Stratagene, La Jolla, 
CA) was reverse transcribed to complementary DNA using the Verso cDNA Kit (Thermo 
Scientific, Waltham, MA). The resulting cDNAs were subjected to PCR for H-Ras (forward: 5’-
GACGGAATATAAGCTGGTGG-3’; reverse: 5’-AGGCACGTCTCCCCATCAAT-3’) and β-
actin (forward: 5’-GGACTTCGAGCAAGAGATGG-3’; reverse: 5’-
AGCACTGTGTTGGCGTACG-3’). PCR products were electrophoresed on agarose gels and 
visualized using ethidium bromide staining. 
 
Immunoblotting 
 Cell lysates were prepared and protein concentrations were measured using the BCA 
assay (Pierce, Rockford, IL), as described previously [4-9]. Equal amounts of cellular proteins 
were resolved by electrophoresis in 8%, 10% or 12% sodium dodecyl sulfate-polyacrylamide 
gels and transferred to nitrocellulose membranes for immunoblotting, using specific antibodies to 
detect H-Ras, Raf-1, phosphorylated Erk1/2 (p-Erk1/2), Erk1/2, Nox-1, EpCAM, E-cadherin, 
MMP-9, Vimentin, β-actin (Santa Cruz Biotechnology, Santa Cruz, CA), p-Raf-1, p-Mek1/2 and 
Mek1/2 (Cell Signaling). Antigen-antibody complexes on membraness were detected by the 







The Student t test was used to analyze statistical significance, indicated by * P<0.05, 
 **P<0.01, and *** P<0.001; a P value <0.05 was considered significant. 
 
Results 
Exposure-dependent enhancement of cancer-associated properties by combined 
carcinogens 
 To investigate the ability of combined NNK and B[α]P (NB) to enhance PhIP-induced 
breast cell carcinogenesis, we repeatedly exposed MCF10A cells to PhIP in the absence and 
presence of NB for 5, 10, 15, and 20 cycles.  Then, we measured the degrees of two acquired 
cancer-associated properties to assess the progression of cellular carcinogenesis.  Growth factors 
and cellular adhesion to the extracellular matrix are required for normal epithelial cell survival; 
in contrast, cancerous cells acquire a reduced dependence on growth factors (RDGF) and 
anchorage-independent growth (AIG) to increase aberrant survival [40].  As shown in Figures 
3.1A-1 and 3.1A-2, cumulative exposures to individual or combined NB and PhIP resulted in 
increasing acquisition of RDGF and AIG in an exposure-dependent manner.  NB and PhIP 
exhibited comparable abilities to induce cellular acquisition of these cancer-associated 
properties; combined NB and PhIP (NBP) exhibited significantly higher abilities than individual 
agents to increase acquisition of these properties.  
 To further understand the exposure-dependent nature of NBP-induced carcinogenesis, we 
established MCF10A-NBP5, -NBP10, -NBP15, and -NBP20 cell lines resulting from repeated 
exposures of MCF10A cells to NBP for 5, 10, 15, and 20 cycles, respectively.  We investigated 
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additional cancer-associated properties acquired by these NBP-induced cell lines and used the 
MCF10A-Ras cell line [41], in which oncogenic H-Ras is ectopically expressed in MCF10A 
cells, as a malignant control.  ROS elevation and increased cell proliferation are closely 
associated with cellular transformation [40].  As shown in Figures 3.1B-1 and 3.1B-2, 
cumulative exposure to NBP resulted in increased ROS elevation and cell proliferation in these 
cell lines in an exposure-dependent manner.  Upregulation of the Ras-ERK pathway contributes 
to increased cell proliferation and leads to expression of NADPH oxidase-1 (Nox-1), which 
mediates non-mitochondrial production of ROS [42].  We detected that H-Ras gene expression 
was increasingly upregulated by cumulative exposures to NBP (Figure 3.1B-3); H-Ras protein 
level, phosphorylation of downstream kinases Raf-1, Mek1/2, and Erk1/2, as well as Nox-1 
expression were accordingly upregulated in these cells (3.1B-4).  These results indicate that the 
Ras-ERK-Nox pathway was activated in concert with progression of NBP-induced breast cell 
carcinogenesis.  
 Stem-like cells and the EMT program play important roles in various stages of cancer 
development [40].  Our previous studies suggested that acquisition of stem-like cell- and EMT-
associated properties is associated with breast cell carcinogenesis [8,9].  Mammary stem-like 
cells have a unique ability to form discrete non-adherent mammospheres and have high levels of 
aldehyde dehydrogenase (ALDH) activity [43,44].  As shown in Figures 3.1B-5 and 3.1B-6, both 
the number of mammospheres and the population of ALDH-positive cells were progressively 
increased by cumulative exposures to NBP.  The ability to develop stem-like cells is associated 
with activation of the EMT program, which confers cells with mesenchymal properties such as 
increased migration and invasion [40].  As shown in Figure 3.1B-7, the epithelial cell markers 
EpCAM and E-cadherin and the EMT markers MMP-9 and Vimentin were reduced and 
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increased, respectively, in concert with NBP-induced cellular carcinogenesis and increased stem-
like cell populations.  In addition, the EMT-associated properties of cell migration (3.1B-8) and 
invasion (3.1B-9) were also accordingly increased.  These results, taken together, indicate that 
cumulative exposures to physiologically-achievable doses of NB and PhIP in combination were 
able to enhance cellular acquisition of cancer-associated properties, including stem-like and 
mesenchymal cell properties, in an exposure-dependent manner.  
 
Enhanced initiation of cellular carcinogenesis by combined carcinogens 
 To investigate the mechanisms of NB in enhancing PhIP-induced cellular carcinogenesis, 
we studied the ability of NB, PhIP, and NBP to induce transient endpoints that are essential for 
induction of cellular carcinogenesis in a single exposure [7,9].  We detected that a single NBP 
exposure induced higher levels of DNA damage (Figure 3.2A-1), ROS elevation (3.2A-2), cell 
proliferation (3.2A-3), Ras gene upregulation (3.2A-4), Ras-ERK activation, and Nox-1 
upregulation (3.2A-5) than either NB or PhIP. These results indicate that co-exposure to NB 
enhanced the ability of PhIP to induce these transient endpoints.  It has been reported that ROS 
elevation may lead to activation of the ERK pathway, and activation of the ERK-Nox pathway 
induces ROS elevation [42,45,46].  To elucidate whether ROS elevation and the ERK-Nox 
pathway interplayed during NB-, PhIP-, and NBP-initiated cellular carcinogenesis, we studied 
the time course of ROS elevation and ERK pathway activation.  We detected that NB, PhIP, and 
NBP induced distinct profiles of ROS elevation (Figure 3.2B-1 & 3.2B-2) and ERK pathway 
activation (3.2C-1 & 3.2C-2).  NBP exposure promptly induced ROS to maximal levels in 6 hr, 
while NB and PhIP progressively induced ROS to maximal levels in 12 and 24 hr, respectively; 
NBP induced significantly higher levels of ROS than NB or PhIP (3.2B-1 & 3.2B-2).  These 
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carcinogens induced ERK activation reaching maximal levels by 24 hr; however, NBP induced 
higher degrees of ERK activation than either NB or PhIP (3.2C-1 & 3.2C-2).  These results 
indicate that NB and NBP induced ROS elevation prior to ERK pathway activation, and PhIP 
induced ROS elevation and ERK activation in parallel; both Nox-dependent and -independent 
ROS elevations were involved in initiation of cellular carcinogenesis by NB, PhIP, and NBP.  
Co-exposure to NB not only significantly increased but also accelerated PhIP-induced ROS 
elevation and ERK pathway activation.  These data suggest that ROS elevation and the ERK-
Nox pathway may interplay during initiation of cellular carcinogenesis. 
 
ROS and the Ras-ERK pathway in initiation and maintenance of cellular carcinogenesis 
 To address whether ROS elevation cross-talked with the ERK pathway, we used the 
Mek1/2 inhibitor U0126 to block ERK pathway (Figure 3.3A-1) and the general antioxidant N-
acetyl-L-cysteine (NAC) to block ROS (3.3A-2).  Treatment with U0126 blocked NB-, PhIP-, 
and NBP-induced ERK activation and Nox-1 elevation, but did not significantly affect H-Ras 
expression (3.3A-1).  U0126 treatment failed to reduce NB-induced ROS elevation but 
significantly reduced PhIP- and NBP-induced ROS (3.3A-2), indicating the role of ERK 
activation in ROS elevation induced by PhIP and NBP, but not NB.  NAC treatment reduced 
NB-, PhIP-, and NBP-induced H-Ras expression, ERK activation, and Nox-1 elevation (3.3A-1), 
indicating the role of ROS elevation in activation of the Ras-ERK-Nox pathway by all these 
carcinogens.  Accordingly, ROS elevation and the ERK pathway mutually interplayed in the 
initiation of cellular carcinogenesis induced by PhIP or NBP; in contrast, ROS elevation led to 
ERK activation during NB-initiated carcinogenesis.  Blockage of either ROS elevation or ERK 
pathway activation significantly suppressed cell proliferation and DNA damage induced by all 
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these carcinogens (Figure 3.3A-3 & 3.3A-4), indicating that ROS elevation and ERK pathway 
activation were essential for increased cell proliferation and DNA damage during the initiation of 
cellular carcinogenesis by NB, PhIP, and NBP.  However, how ROS elevation results in ERK 
pathway activation by NB remains to be investigated.   
 To validate the roles of ROS elevation and ERK pathway activation in the progression of 
cellular carcinogenesis, we repeatedly exposed MCF10A cells to NB, PhIP, or NBP in the 
absence and presence of U0126 or NAC for 10 cycles.  Blockage of either the ERK pathway or 
ROS elevation in each cycle resulted in significant suppression of cellular acquisition of RDGF, 
AIG, cell migration, and invasion after accumulated exposures (Figures 3.3B-1 to 3.3B-4).  
These results indicate that inhibition of either the ERK pathway or ROS elevation in each 
exposure cycle effectively blocked progression of carcinogenesis induced by cumulative 
exposures to carcinogens.  
 
Ergosterol and mimosine intervened in cellular carcinogenesis  
 Co-exposure to NB was able to significantly enhance PhIP’s ability to induce cellular 
carcinogenesis.  Identifying dietary agents effective in intervention of NBP-induced cellular 
carcinogenesis is an affordable option for prevention of breast cancer.  Considering the toxicity 
resulting from long-term use of anticancer agents, use of dietary agents at non-cytotoxic levels 
should be adopted as the key strategy for cancer prevention.  In searching for optimal dietary 
agents, we detected that ergosterol and mimosine were effective in suppressing NBP-induced 
cellular carcinogenesis.  Initially, by measuring the effects of various concentrations of 
ergosterol and mimosine individually on MCF10A cell viability, we determined the non-
cytotoxic concentrations of ergosterol at ≤1 µmol/L and mimosine at ≤5 µmol/L (Figures 3.4A-1 
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to 3.4A-2).  Subsequently, we determined that a combination of ≤0.5 µmol/L ergosterol and ≤0.5 
µmol/L mimosine was not cytotoxic to MCF10A cells (Figure 3.4A-3).  Studies indicated 
physiologically-achievable doses of ergosterol and mimosine at nano-molar levels [36,37]. 
Accordingly, we used 10 nmol/L ergosterol, 10 nmol/L mimosine, and combined 5 nmol/L 
ergosterol and 5 nmol/L mimosine to determine their ability to intervene in NBP-induced cellular 
carcinogenesis.  Using NBP-induced transient endpoints as targets, we detected that ergosterol or 
mimosine was able to suppress NBP-induced DNA damage (Figure 3.5A-1), ROS elevation 
(3.5A-2), cell proliferation (3.5A-3), and Ras-ERK-Nox pathway activation (3.5A-4); a 
combination of ergosterol and mimosine completely blocked these NBP-induced transient 
endpoints.  To validate the ability of ergosterol and mimosine to intervene with progression of 
carcinogenesis induced by cumulative exposures to NBP, we repeatedly exposed MCF10A cells 
to NBP in the absence and presence of ergosterol and mimosine individually and in combination 
for 10 cycles.  Exposure to either ergosterol or mimosine simultaneously with NBP significantly 
reduced cellular acquisition of RDGF (Figure 3.5B-1), AIG (3.5B-2), ROS elevation (3.5B-3), 
increased cell proliferation (3.5B-4), and Ras-ERK-Nox pathway activation (3.5B-5).  Exposure 
to either ergosterol or mimosine also significantly reduced mammosphere formation (3.5B-6), 
ALDH-positive cell population (3.5B-7), and the EMT-associated markers MMP-9 and Vimentin 
(3.5B-8), as well as decreased the EMT- and cancer-associated properties of cell migration 
(3.5B-9), invasion (3.5B-10), and motility (3.5C-1 & 3.5C-2).  Combined ergosterol and 
mimosine was more effective than either agent in suppressing these properties and appeared to 
completely suppress cellular acquisition of all cancer-associated properties (3.5B-1 to 3.5B-10, 
3.5C-1 & 3.5C-2).  Thus, ergosterol plus mimosine appeared to be the optimal combination for 
intervention of cellular carcinogenesis induced by long-term exposure to NBP. 
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Ergosterol and mimosine suppressed oxidative DNA damage induced by carcinogens 
 DNA damage, resulting from ROS-mediated oxidation, is an underlying cause of cellular 
carcinogenesis [40,47].  ROS elevation was essential for initiation of NBP-induced cellular 
carcinogenesis.  To further understand if ROS-mediated oxidation of DNA was involved in DNA 
damage induced by carcinogens, we used the repair endonuclease Fpg.  Fpg removes oxidized 
DNA bases to cause broken strands that are detectable with a modified comet assay [39].  We 
detected that DNA oxidation was induced in concert with DNA damage induced by NNK, 
B[α]P, NB, PhIP, and NBP (Figure 3.6A-1 & 3.6A-2); blockage of ROS elevation by NAC 
suppressed DNA oxidation (3.6B-1 & 3.6B-2), indicating that ROS-mediated oxidation of DNA 
was involved in carcinogen-induced DNA damage.  
 Both ergosterol and mimosine were able to reduce NBP-induced ROS elevation and 
DNA damage.  To determine if ergosterol and mimosine were able to block carcinogen-induced 
DNA oxidation, we treated cells with carcinogens in the absence and presence of ergosterol 
and/or mimosine.  We detected that combined ergosterol and mimosine was more effective than 
individual agents in suppression of DNA damage, ROS elevation, and DNA oxidation induced 
by carcinogens (Figures 3.6C-1 to 3.6C-3).  These results indicate the antioxidant ability of 
ergosterol and mimosine to protect chromosomal DNA from oxidative damage in cells during 
exposure to NNK, B[α]P, and PhIP. 
 
Induction of cellular carcinogenesis in MCF12A cells and suppression by ergosterol and 
mimosine  
 To investigate whether the ability of NB to enhance PhIP-induced cellular carcinogenesis 
and the effectiveness of ergosterol and mimosine in intervention of breast cell carcinogenesis 
159 
 
were limited to the estrogen receptor (ER)-negative MCF10A cell line, we performed studies on 
the non-cancerous human breast epithelial ER-positive MCF12A cell line, which is unrelated to 
MCF10A cells.  Based on the results of non-cytotoxic concentrations of ergosterol and mimosine 
on MCF12A cells (Figures 3.4B-1 to 3.4B-3), we again used 10 nmol/L ergosterol, 10 nmol/L 
mimosine, and combined 5 nmol/L ergosterol and 5 nmol/L mimosine.  Consistently, NB co-
exposure enhanced PhIP-induced transient endpoints of DNA damage, ROS elevation, cell 
proliferation, and Ras-ERK-Nox pathway in MCF12A cells in a single cycle and combined 
ergosterol and mimosine were more effective than individual agents in suppression of these 
transient endpoints (Figures 3.7A-1 to 3.7A-4).  After 20 cycles of exposure, we detected that 
cells exposed to NBP acquired significantly higher degrees of all the measured cancer-associated 
properties than cells exposed to either NB or PhIP; these cancer-associated properties included 
RDGF, AIG, ROS elevation, increased cell proliferation, Ras-ERK-Nox pathway activation, 
mammosphere formation, enriched stem-like cell population, EMT markers, cell migration, and 
cell invasion (Figures 3.7B-1 to 3.7B-10).  To verify the ability of ergosterol and mimosine to 
intervene in NBP-induced cancer-associated properties, we repeatedly exposed MCF12A cells to 
NBP in the absence and presence of ergosterol and mimosine individually and in combination for 
10 cycles.  We detected that combined ergosterol and mimosine was more effective than either 
agent in suppressing NBP-induced cancer-associated properties, and combined ergosterol and 
mimosine completely suppressed cellular acquisition of cancer-associated properties induced by 
cumulative exposures to NBP (Figures 3.7B-1 to 3.7B-10).  Thus, the ability of co-exposure to 
NB to enhance PhIP-induced cellular carcinogenesis and the ability of ergosterol and mimosine 





 In this communication, we demonstrated that cumulative co-exposures to 
physiologically-achievable levels of multiple environmental and dietary carcinogens resulted in 
enhanced breast cell carcinogenesis.  Nano-molar PhIP and pico-molar NNK and B[α]P are 
physiologically achievable in the human body [10,14,19].  Our model system permits a highly 
relevant approach to determine mechanisms involved in the development of sporadic breast 
cancer associated with long-term exposure to low doses of carcinogens existing in our 
environment and diets.  The findings then can be used as targets for identifying preventive agents 
effective in intervention of cancer development.    
 ROS elevation and ERK pathway activation appeared to play key roles in NBP-induced 
cellular carcinogenesis.  NB and PhIP induced distinct elevation kinetics of ROS, and NB-
exposed cells reached maximal ROS level earlier than PhIP-exposed cells.  Co-exposure to NB 
and PhIP not only accelerated but also significantly increased ROS elevation in cells.  It is 
recognized that ROS are actively mutagenic and contribute to genomic instability that is 
necessary for cellular carcinogenesis [40].  Conversely, NB and PhIP induced similar activation 
kinetics of the ERK pathway and combined NB and PhIP resulted in enhanced activation of the 
ERK pathway over NB or PhIP alone.  ROS elevation and the ERK pathway were mutually 
dependent; blockage of one resulted in suppression of the other.  Our previous studies suggested 
that NB exposure induces ROS elevation leading to ERK pathway activation [7] and that PhIP 
induces Ras-ERK-Nox pathway activation resulting in ROS production [9].  Accordingly, co-
exposure to NB and PhIP induced both ROS to the ERK-Nox pathway and the ERK-Nox 
pathway to ROS elevation simultaneously, resulting in reinforced, accelerated and enhanced 
ROS elevation.  The accelerated and increased ROS levels induced higher levels of DNA 
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oxidation and damage in each exposure cycle, contributing to enhanced initiation of cellular 
carcinogenesis and leading to enhanced acquisition of cancer-associated properties by cells after 
cumulative NBP exposure cycles.  Combined NB and PhIP enhanced cellular acquisition of all 
the cancer-associated properties we tested, including stem-like and mesenchymal cell properties.  
However, whether co-exposure to NB and PhIP may enhance cellular tumorigenicity and 
mammary tumor development in animals, as well as human breast cancer development, remains 
to be determined.   
 In our model system, we use transient and constitutive endpoints as targets to validate 
preventive agents capable of blocking carcinogenesis initiation and suppressing carcinogenesis 
progression, respectively [5-9].  In this communication, we identified two less studied agents, 
ergosterol and mimosine, capable of intervening with NBP-induced breast cell carcinogenesis.  
Both ergosterol and mimosine, at physiologically-achievable non-cytotoxic levels, were effective 
in blocking ROS elevation, Ras-ERK-Nox pathway activation, DNA oxidation, DNA damage, 
and cell proliferation induced by a single NBP exposure, which accounted for their ability to 
suppress constitutive endpoints induced by cumulative NBP exposures.  The combination of 
ergosterol and mimosine was more effective than individual agents in blocking transient and 
constitutive endpoints.  Combined ergosterol and mimosine, used at 5 nmol/L each, was more 
effective than individual agents used at 10 nmol/L, indicating that these two agents may act 
synergistically in suppression of transient and constitutive properties.  It has been suggested that 
prevention strategies making use of combined dietary agents are advantageous over those using 
individual agents due to higher efficacy and lower toxicity [48].  In addition, considering our 
previous [6-9] and current results, combined ergosterol and mimosine appeared to be more 
effective and less cytotoxic than green tea catechins for intervention of breast cell carcinogenesis 
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induced by NB and PhIP.  Thus, ergosterol and mimosine should be seriously considered in 
dietary prevention of sporadic breast cancer associated with long-term exposure to multiple 
environmental and dietary carcinogens.     
 Over 85% of breast cancers are sporadic and attributable to long-term exposure to small 
quantities of carcinogens [2,3].  Long-term exposure to polluted air, smoke, and diets with high-
temperature cooked meats are closely associated with American lifestyles [10,16,20].  In this 
communication, we demonstrated that co-exposure to the environmental carcinogens NNK and 
B[α]P with the dietary carcinogen PhIP resulted in holistically enhanced initiation and 
progression of breast cell carcinogenesis.  Using our model as a target, we demonstrated, for the 
first time, that a combination of two less recognized dietary constituents, ergosterol and 
mimosine, was highly effective in intervention of breast cell carcinogenesis.  Notably, 
NNK/B[a]P/PhIP-enhanced cellular carcinogenesis and ergosterol/mimosine-mediated 
intervention were independent of breast cell type and ER status.  Ergosterol is rich in dietary 
sources, such as mushrooms, morels, and soy sauce, which are readily available in the United 
States [22,23,49].  Mimosine-containing legumes are consumed daily throughout Southeast Asia 
and Central America [50].  Thus, dietary components containing ergosterol and mimosine should 
be seriously considered in the American diet for affordable prevention of sporadic breast cancer.  
However, the roles of long-term human exposure to combined low-dose NNK, B[α]P, and PhIP 
in enhanced sporadic breast cancer development and combined use of ergosterol- and mimosine-
containing dietary components in breast cancer intervention will need epidemiological and 
clinical studies for validation.   
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Figure 3.1. Exposure-dependent enhancement of cancer-associated properties by combined 
carcinogens. (A-1 and A-2) MCF10A (10A) cells were repeatedly exposed to combined 100 
pmol/L NNK and 100 pmol/L B[α]P (NB), 10 nmol/L PhIP (P), or combined NB and PhIP 
(NBP) for 5, 10, 15 and 20 cycles. (B-1 to B-9) MCF10A (10A) cells were repeatedly exposed to 
combined NB and PhIP (NBP) for 5, 10, 15 and 20 cycles resulting in the NBP5, NBP10, and 
NBP15 and NBP20 cell lines, respectively. MCF10A-Ras (Ras) cells were used as a malignant 
control. (A-1) To determine cellular acquisition of reduced dependence on growth factors 
(RDGF), cells were maintained in LM medium for 10 days. Cell colonies ≥0.5 mm diameter 
were counted. (A-2) To determine cellular acquisition of anchorage-independent growth (AIG), 
cells were seeded in soft agar for 14 days. Cell colonies ≥0.1 mm diameter were counted. (B-1) 
ROS levels were measured with CM-H2DCF-DA labeling and normalized by the level 
determined in untreated cells, set as 1 (X, arbitrary unit). (B-2) Relative cell proliferation was 
determined and normalized by the value of BrdU detected in untreated cells, set as 100%. (B-3) 
Total RNA was isolated and analyzed by RT-PCR with specific primers to determine relative 
gene expression levels of H-Ras, with β-actin as a control, and these levels were quantified by 
densitometry. The levels of H-Ras (Ras/actin) were calculated by normalizing with the level of 
β-actin and the level set in untreated control cells as 1 (X, arbitrary unit). (B-4) Cell lysates were 
prepared and analyzed by western immunoblotting using specific antibodies to detect levels of 
H-Ras, phosphorylated-Raf-1 (p-Raf-1), Raf-1, p-Mek1/2, Mek1/2, p-Erk1/2, Erk1/2, and Nox-1, 
with β-actin as a control, and these levels were quantified by densitometry.  The levels of H-Ras 
(Ras/actin) and Nox-1 (Nox/actin) were calculated by normalizing with the level of β-actin and 
the level set in untreated control cells as 1 (X, arbitrary unit). Levels of specific phosphorylation 
of Raf-1 (p/Raf), Mek1/2 (p/Mek) and Erk1/2 (p/Erk) were calculated by normalizing the levels 
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of p-Raf-1, p-Mek1/2 and p-Erk1/2 with the levels of Raf-1, Mek1/2 and Erk1/2, respectively, 
then the level set in control cells as 1 (X, arbitrary unit). (B-5) To determine cellular acquisition 
of serum-independent non-adherent growth (SINAG), cells were seeded in non-adherent cultures 
for 10 days. Mammospheres ≥0.1 mm diameter were counted. (B-6) Mammospheres were 
collected and trypsinized, and ALDH-expressing (ALDH
+
) cell population (%) was measured by 
flow cytometry. (B-7) Cell lysates were prepared and analyzed by western immunoblotting using 
specific antibodies to detect levels of EpCAM, E-cadherin, MMP-9 and Vimentin, with β-actin 
as a control, and these levels were quantified by densitometry. The levels of EpCAM 
(EpCAM/actin), E-cadherin (E-cad/actin), MMP-9 (MMP/actin), and Vimentin (Vim/actin) were 
calculated by normalizing with the level of β-actin and the level set in untreated control cells as 1 
(X, arbitrary unit). (B-8) Cellular migratory and (B-9) invasive activities were determined by 
counting the numbers of cells translocated through a polycarbonate filter without or with coated 
Matrigel, respectively, in 10 arbitrary visual fields. Columns, mean of triplicates; bars, SD. All 
results are representative of three independent experiments. Statistical significance is indicated 
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Figure 3.2. Enhanced initiation of cellular carcinogenesis by combined carcinogens. (A-1 to 
A-5) MCF10A cells were exposed to combined 100 pmol/L NNK and 100 pmol/L B[α]P (NB), 
10 nmol/L PhIP (P), or combined NB and PhIP (NBP) for 24 h. (B-1 to C-2) MCF10A cells were 
exposed to combined 100 pmol/L NNK and 100 pmol/L B[α]P (NB), 10 nmol/L PhIP (P), or 
combined NB and PhIP (NBP) for 6, 12, 24 and 48 h. (A-1) DNA damage was measured by a 
comet assay and normalized by the value of average tail moment determined in untreated 
counterpart cells, set as 1 (X, arbitrary unit). Representative images detected in the comet assay 
are shown. (A-2, B-1 and B-2) ROS levels were measured with CM-H2DCF-DA labeling and 
normalized by the level determined in untreated cells, set as 1 (X, arbitrary unit). (A-3) Relative 
cell proliferation was determined and normalized by the value of BrdU detected in untreated 
cells, set as 100%. (A-4) Total RNA was isolated and analyzed by RT-PCR with specific primers 
to determine relative gene expression levels of H-Ras, with β-actin as a control, and these levels 
were quantified by densitometry. The levels of H-Ras (Ras/actin) were calculated by normalizing 
with the level of β-actin and the level set in untreated control cells as 1 (X, arbitrary unit). (A-5) 
Cell lysates were prepared and analyzed by western immunoblotting using specific antibodies to 
detect levels of H-Ras, phosphorylated-Erk1/2 (p-Erk1/2), Erk1/2, and Nox-1, with β-actin as a 
control, and these levels were quantified by densitometry. The levels of H-Ras (Ras/actin) and 
Nox-1 (Nox/actin) were calculated by normalizing with the level of β-actin and the level set in 
untreated control cells as 1 (X, arbitrary unit). Levels of specific phosphorylation of Erk1/2 
(p/Erk) were calculated by normalizing the levels of p-Erk1/2 with the levels of Erk1/2, then the 
level set in control cells as 1 (X, arbitrary unit). (C-1 and C-2) Cell lysates were prepared and 
analyzed by western immunoblotting using specific antibodies to detect levels of p-Erk1/2 and 
Erk1/2 and these levels were quantified by densitometry. The levels of specific phosphorylation 
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of Erk1/2 (p/Erk) were calculated by normalizing the levels of p-Erk1/2 with the levels of 
Erk1/2, then the level set in control cells as 1 (X, arbitrary unit). Columns, mean of triplicates; 
bars, SD. All results are representative of three independent experiments. Statistical significance 
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Figure 3.3. ROS and the Ras-ERK pathway in initiation and maintenance of cellular 
carcinogenesis. (A-1 to A-4) MCF10A (10A) cells were exposed to 10 µmol/L U0126 (U) or 5 
mmol/L NAC (N) for 24 h; MCF10A cells were exposed to combined 100 pmol/L NNK and 100 
pmol/L B[α]P (NB), 10 nmol/L PhIP (P), or combined NB and PhIP (NBP) in the absence and 
presence of 10 µmol/L U0126 (U0) or 5 mmol/L NAC for 24 h. (B-1 to B-4) MCF10A (10A) 
cells were treated with 10 µmol/L U0126 (U) or 5 mmol/L NAC (N) for 10 cycles resulting in 
the 10A/U10 and 10A/N10 cell lines; MCF10A cells were exposed to combined 100 pmol/L 
NNK and 100 pmol/L B[α]P (NB), 10 nmol/L PhIP (P), or combined NB and PhIP (NBP) in the 
absence and presence of 10 µmol/L U0126 (U) or 5 mmol/L NAC (N) for 10 cycles resulting in 
the NB10, NB/U10, NB/N10, P10, P/U10, P/N10, NBP10 NBP/U10 and NBP/N10 cell lines 
respectively. (A-1) Cell lysates were prepared and analyzed by western immunoblotting using 
specific antibodies to detect levels of H-Ras, p-Erk1/2, Erk1/2, and Nox-1, with β-actin as a 
control, and these levels were quantified by densitometry. The levels of H-Ras (Ras/actin) and 
Nox-1 (Nox/actin) were calculated by normalizing with the level of β-actin and the level set in 
untreated control cells as 1 (X, arbitrary unit). Levels of specific phosphorylation of Erk1/2 
(p/Erk) were calculated by normalizing the levels of p-Erk1/2 with the levels of Erk1/2, then the 
level set in control cells as 1 (X, arbitrary unit). (A-2) ROS levels were measured with CM-
H2DCF-DA labeling and normalized by the level determined in untreated cells, set as 1 (X, 
arbitrary unit). (A-3) Relative cell proliferation was determined and normalized by the value of 
BrdU detected in untreated cells, set as 100%. (A-4) DNA damage was measured by a comet 
assay and normalized by the value of average tail moment determined in untreated counterpart 
cells, set as 1 (X, arbitrary unit). (B-1) To determine cellular acquisition of reduced dependence 
on growth factors (RDGF), cells were maintained in LM medium for 10 days. Cell colonies ≥0.5 
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mm diameter were counted.  (B-2) To determine cellular acquisition of anchorage-independent 
growth (AIG), cells were seeded in soft agar for 14 days. Cell colonies ≥0.1 mm diameter were 
counted. (B-3) Cellular migratory and (B-4) invasive activities were determined by counting the 
numbers of cells translocated through a polycarbonate filter without or with coated Matrigel, 
respectively, in 10 arbitrary visual fields. Columns, mean of triplicates; bars, SD. All results are 
representative of three independent experiments. Statistical significance is indicated by * P<0.05, 

















Figure 3.4. Cytotoxicity of ergosterol and mimosine in MCF10A and MCF12A cell lines. 
(A-1 to A-3) MCF10A cells or (B-1 to B-3) MCF12A cells were treated with 100pM, 1nM, 
10nM, 100nM, 1µM, 5µM, 20µM and 50µM ergosterol and mimosine individually, or combined 
in equal parts. Quantification of cell viability was determined with an MTT Assay Kit, and 
relative cell viability was normalized by the value determined in untreated counterpart cells, set 
as 100%. Columns, mean of triplicates; bars, SD. All results are representative of three 
independent experiments. Statistical significance is indicated by * P<0.05, ** P<0.01, and *** 













Figure 3.5. Ergosterol and mimosine intervened in cellular carcinogenesis. (A-1 to A-4) 
MCF10A cells were exposed to 100 pmol/L NNK, 100 pmol/L B[α]P, and 10 nmol/L PhIP 
(NBP) in the absence and presence of 10nM ergosterol (E), 10nM mimosine (M), or combined 
ergosterol and mimosine (E+M) at 5nM each for 24 h. (B-1 to C-2) MCF10A cells were exposed 
to 100 pmol/L NNK, 100 pmol/L B[α]P, and 10 nmol/L PhIP (NBP) in the absence and presence 
of 10nM ergosterol (E), 10nM mimosine (M), or combined ergosterol and mimosine (E+M) at 
5nM each for 10 cycles resulting in the NBP10, NBP/E10, NBP/M10 and NBP/E+M10 cell 
lines, respectively. (A-1) DNA damage was measured by a comet assay and normalized by the 
value of average tail moment determined in untreated counterpart cells, set as 1 (X, arbitrary 
unit). Representative images detected in the comet assay are shown. (A-2 and B-3) ROS levels 
were measured with CM-H2DCF-DA labeling and normalized by the level determined in 
untreated cells, set as 1 (X, arbitrary unit). (A-3 and B-4) Relative cell proliferation was 
determined and normalized by the value of BrdU detected in untreated cells, set as 100%. (A-4 
and B-5) Cell lysates were prepared and analyzed by western immunoblotting using specific 
antibodies to detect levels of H-Ras, p-Erk1/2, Erk1/2, and Nox-1, with β-actin as a control, and 
these levels were quantified by densitometry. The levels of H-Ras (Ras/actin) and Nox-1 
(Nox/actin) were calculated by normalizing with the level of β-actin and the level set in untreated 
control cells as 1 (X, arbitrary unit). Levels of specific phosphorylation of Erk1/2 (p/Erk) were 
calculated by normalizing the levels of p-Erk1/2 with the levels of Erk1/2, then the level set in 
control cells as 1 (X, arbitrary unit). (B-1) To determine cellular acquisition of reduced 
dependence on growth factors (RDGF), cells were maintained in LM medium for 10 days. Cell 
colonies ≥0.5 mm diameter were counted. (B-2) To determine cellular acquisition of anchorage-
independent growth (AIG), cells were seeded in soft agar for 14 days. Cell colonies ≥0.1 mm 
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diameter were counted. (B-6) To determine cellular acquisition of serum-independent non-
adherent growth (SINAG), cells were seeded in non-adherent cultures for 10 days. 
Mammospheres ≥0.1 mm diameter were counted. (B-7) Mammospheres were collected and 
trypsinized, and ALDH-expressing (ALDH
+
) cell population (%) was measured by flow 
cytometry. (B-8) Cell lysates were prepared and analyzed by western immunoblotting using 
specific antibodies to detect levels of EpCAM, E-cadherin, MMP-9 and Vimentin, with β-actin 
as a control, and these levels were quantified by densitometry. The levels of EpCAM 
(EpCAM/actin), E-cadherin (E-cad/actin), MMP-9 (MMP/actin), and Vimentin (Vim/actin) were 
calculated by normalizing with the level of β-actin and the level set in untreated control cells as 1 
(X, arbitrary unit). (B-9) Cellular migratory and (B-10) invasive activities were determined by 
counting the numbers of cells translocated through a polycarbonate filter without or with coated 
Matrigel, respectively, in 10 arbitrary visual fields. (C-1) Cellular acquisition of increased 
motility was determined by wound healing assay. The wounded areas were examined 
(magnification, 100×) 6, 12, and 24 h afterward. Arrows indicate width of wounded areas. (C-2)  
To quantitatively measure cell motility detected in F-1, the area not healed by the cells was 
subtracted from the total area of the initial wound to calculate the wound healing area (%) at 
intervals of 6 (white columns), 12 h (light gray columns) and 24 h (dark gray columns). 
Columns, mean of triplicates; bars, SD. All results are representative of three independent 
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Figure 3.6. Ergosterol and mimosine suppressed oxidative DNA damage induced by 
carcinogens. (A-1 and A-2) MCF10A cells were exposed to 100 pmol/L NNK (N), 100 pmol/L 
B[α]P (B), combined NNK and B[α]P (NB), 10 nmol/L PhIP (P), or combined NB and PhIP 
(NBP) for 24 h. (B-1 and B-2) MCF10A cells were exposed to N, B, combined NB, P, or 
combined NBP in the absence and presence of 5 mmol/L NAC for 24 h. (C-1 to C-3) MCF10A 
cells were exposed to N, B, combined NB, P, or combined NBP in the absence and presence of 
10nM ergosterol (E), 10nM mimosine (M), or combined ergosterol and mimosine (E+M) at 5nM 
each for 24 h. (A-1 and C-1) DNA damage was measured by a comet assay and normalized by 
the value of average tail moment determined in untreated counterpart cells, set as 1 (X, arbitrary 
unit). Representative images detected in the comet assay are shown. (A-2, B-2 and C-3) DNA 
oxidation was measured by an Fpg modified comet assay and reported as the difference in tail 
moment between Fpg treated and non-Fpg treated cells and normalized by the value of average 
tail moment determined in untreated counterpart cells, set as 1 (X, arbitrary unit). (B-1 and C-2) 
ROS levels were measured with CM-H2DCF-DA labeling and normalized by the level 
determined in untreated cells, set as 1 (X, arbitrary unit). Columns, mean of triplicates; bars, SD. 
All results are representative of three independent experiments. Statistical significance is 
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Figure 3.7. Induction of cellular carcinogenesis in MCF12A cells and suppression by 
ergosterol and mimosine. (A-1 to A-4) MCF12A cells (12A) were exposed to combined 100 
pmol/L NNK and 100 pmol/L B[α]P (NB), 10 nmol/L PhIP (P), combined NB and PhIP (NBP) 
and NBP in the presence of 10nM ergosterol (E), 10nM mimosine (M), or combined ergosterol 
and mimosine (E+M) at 5nM each for 24 h. (B-1 to B-10) MCF12A cells (12A) were repeatedly 
exposed to combined 100 pmol/L NNK and 100 pmol/L B[α]P (NB), 10 nmol/L PhIP (P), or 
combined NB and PhIP (NBP) for 20 cycles; MCF12A cells (12A) were repeatedly exposed to 
combined NB and PhIP (NBP) in the absence and presence of 10nM ergosterol (E), 10nM 
mimosine (M), or combined ergosterol and mimosine (E+M) at 5nM each for 10 cycles. (A-1) 
DNA damage was measured by a comet assay and normalized by the value of average tail 
moment determined in untreated counterpart cells, set as 1 (X, arbitrary unit). Representative 
images detected in the comet assay are shown. (A-2 and B-3) ROS levels were measured with 
CM-H2DCF-DA labeling and normalized by the level determined in untreated cells, set as 1 (X, 
arbitrary unit). (A-3 and B-4) Relative cell proliferation was determined and normalized by the 
value of BrdU detected in untreated cells, set as 100%. (A-4 and B-5) Cell lysates were prepared 
and analyzed by western immunoblotting using specific antibodies to detect levels of H-Ras, p-
Erk1/2, Erk1/2, and Nox-1, with β-actin as a control, and these levels were quantified by 
densitometry. The levels of H-Ras (Ras/actin) and Nox-1 (Nox/actin) were calculated by 
normalizing with the level of β-actin and the level set in untreated control cells as 1 (X, arbitrary 
unit). Levels of specific phosphorylation of Erk1/2 (p/Erk) were calculated by normalizing the 
levels of p-Erk1/2 with the levels of Erk1/2, then the level set in control cells as 1 (X, arbitrary 
unit). (B-1) To determine cellular acquisition of reduced dependence on growth factors (RDGF), 
cells were maintained in LM medium for 10 days. Cell colonies ≥0.5 mm diameter were counted. 
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(B-2) To determine cellular acquisition of anchorage-independent growth (AIG), cells were 
seeded in soft agar for 14 days. Cell colonies ≥0.1 mm diameter were counted. (B-6) To 
determine cellular acquisition of serum-independent non-adherent growth (SINAG), cells were 
seeded in non-adherent cultures for 10 days. Mammospheres ≥0.1 mm diameter were counted. 
(B-7) Mammospheres were collected and trypsinized, and ALDH-expressing (ALDH
+
) cell 
population (%) was measured by flow cytometry. (B-8) Cell lysates were prepared and analyzed 
by western immunoblotting using specific antibodies to detect levels of EpCAM, E-cadherin, 
MMP-9 and Vimentin, with β-actin as a control, and these levels were quantified by 
densitometry. The levels of EpCAM (EpCAM/actin), E-cadherin (E-cad/actin), MMP-9 
(MMP/actin), and Vimentin (Vim/actin) were calculated by normalizing with the level of β-actin 
and the level set in untreated control cells as 1 (X, arbitrary unit). (B-9) Cellular migratory and 
(B-10) invasive activities were determined by counting the numbers of cells translocated through 
a polycarbonate filter without or with coated Matrigel, respectively, in 10 arbitrary visual fields. 
Columns, mean of triplicates; bars, SD. All results are representative of three independent 
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 The research presented in this dissertation was designed to (1) investigate the ability, and 
associated mechanisms, of NB to enhance PhIP-induced chronic breast cell carcinogenesis (2) 
evaluate the efficacy of combined dietary agents, such as green tea catechins, ergosterol and 
mimosine, in intervention of breast cell carcinogenesis induced by chronic exposure to combined 
environmental and dietary carcinogens.  
 
Enhancement of Chronically Induced Breast Cell Carcinogenesis by Combined 
Environmental and Dietary Carcinogens 
 The activity of low doses of multiple carcinogens to induce breast cell carcinogenesis is 
an under-investigated area. Since we are all exposed to various carcinogens each day from our 
environment and diet, it is important to examine the biochemical and molecular mechanisms and 
pathways associated with cellular carcinogenesis induced by each carcinogen and how these 
factors interact when carcinogens are combined. Our model system presents several unique 
features to advance our understanding of sporadically-occurring human breast carcinogenesis. It 
is highly sensitive to detect low physiologically-achievable doses of either weak or potent 
carcinogens capable of inducing breast cell carcinogenesis, it exposes cells to carcinogens in a 
cumulative manner to mimic progressive induction of chronic carcinogenesis, and it provides 
measurable transient and constitutive cellular, biochemical, and molecular endpoints to 
determine the induction and progression of cellular carcinogenesis. In contrast, most existing 
systems study the activity of carcinogens at high concentrations for acute induction of cellular 
carcinogenesis [1-8]. However, since most human cancers result from long-term exposure to low 
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doses of carcinogens, a chronic low-dose approach is a more relevant way to study the effects of 
environmental carcinogens on human breast cancer development.  
Using our cellular model, we demonstrated the ability of the relatively weak mammary 
carcinogens NNK and B[α]P (NB) to enhance breast cell carcinogenesis induced by potent 
mammary carcinogen PhIP [9]. In addition, we characterized the mechanisms of NB-mediated 
enhancement of PhIP-induced cellular carcinogenesis [10]. Our studies revealed that either pre- 
or co-exposure to NB significantly enhanced cellular carcinogenesis induced by PhIP, with co-
exposure being the most potent [9]. MCF10A cells repeatedly exposed to combined NB and 
PhIP (NBP) increasingly acquired cancer-associated properties in an exposure-dependent manner 
to significantly higher levels than cells exposed to either NB or PhIP alone [9, 10]. Cumulative 
exposures to NBP resulted in enhanced acquisition of the cancer-associated properties of reduced 
dependence on growth factors and anchorage-independent growth, the stem-like cell properties 
of increased mammosphere formation and ALDH-positive cell population and the EMT-
associated properties of increased cell migration, invasion and motility [10]. Although induction 
of the EMT program and development of stem-like cells have been postulated to play important 
roles in cancer development and progression [11], enriched stem-like cell population is not yet 
fully appreciated as a breast cancer-associated property. Applying our model system has 
advanced our understanding of the involvement of EMT and stem-like cells during breast cell 
carcinogenesis and our results suggest that activation of the EMT program and increased stem-
like cell population should be considered as novel cancer-associated properties used to measure 
the progression of breast cell carcinogenesis. 
Mechanistic studies revealed that transient ROS elevation induced by short-term 
exposure to NBP played a key role in activating the Ras-ERK-Nox pathway, leading to increased 
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cellular proliferation [10]. Hyperproliferation and elevated ROS levels increased cellular 
susceptibility to chromosomal DNA damage and oxidation, which is essential for the induction 
of cellular carcinogenesis [11]. Ras-ERK pathway-mediated induction of Nox-1 potentiated ROS 
elevation and facilitated the interplay that occurred between the ERK pathway and ROS 
production, both of which were required for the initiation and maintenance of NBP-induced 
cancer-associated properties. Co-exposure to NB enhanced the capability of PhIP to induce these 
transient endpoints during each exposure cycle enabling enhanced initiation of cellular 
carcinogenesis and ultimately contributing to enhanced acquisition of cancer-associated, stem-
like and mesenchymal cell properties after cumulative exposures. We demonstrated that cellular 
exposure to carcinogens can stimulate ROS-mediated Ras-ERK pathway signaling providing 
evidence for the involvement of ROS as important signaling modulators during induction and 
progression of cellular carcinogenesis induced by chronic carcinogen exposure.   
 
Intervention of Chronic Breast Cell Carcinogenesis by Combined Dietary Agents 
Use of combined dietary agents has gained traction in recent years as an effective strategy 
for preventing human cancer development. Prevention strategies making use of combined dietary 
agents are advantageous over those using individual agents due to higher efficacy and lower 
toxicity [12]. Since carcinogenesis occurs in a multi-step process, a variety of agents with 
complementary modes of action are needed to effectively suppress this complex disease. 
Accordingly, there have been numerous studies that support the use of combined dietary agents 
for the prevention of various malignancies including breast cancer [13-21]. In this research, we 
used our cellular model as a target system to identify novel combinations of dietary agents 
effective in intervention of breast cell carcinogenesis induced by chronic exposure to 
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environmental and dietary carcinogens. We employed a two-step strategy which initially used 
short-term biological, biochemical and molecular endpoints transiently induced by carcinogen 
exposure as targets to identify dietary agents that can block cellular carcinogenesis.  The second 
step subsequently used long-term cellular acquisition of cancer-associated properties, including 
stem-like and mesenchymal cell properties, induced by chronic carcinogen exposure to validate 
the ability of preventive dietary agents to suppress cellular carcinogenesis. 
Using our cellular model as a target system, we were able to verify the enhanced 
preventive activity of combined green tea catechins ECG and EGCG and combined ergosterol 
and mimosine, at non-cytotoxic levels, in suppression of NBP-induced chronic cellular 
carcinogenesis. In addition, we have identified the mechanisms through which these agents can 
counteract the biological, biochemical, and molecular effects of exposure to NNK, B[α]P and 
PhIP. We have shown that green tea catechins, ergosterol and mimosine, when used individually 
or in combination, are capable of blocking NBP-induced transient ROS elevation, ERK pathway 
activation, cell proliferation and chromosomal DNA damage, which accounted for the cytotoxic-
independent ability of these agents to suppress cellular acquisition of cancer-associated, stem-
like and mesenchymal cell properties. We also revealed the ability of ergosterol and mimosine to 
protect chromosomal DNA from oxidative damage caused by carcinogen-induced ROS.  
Although ECG was slightly more effective than EGCG, and mimosine was slightly more 
effective than ergosterol, a combination of green tea catechins, and of ergosterol and mimosine, 
were more effective than individual agents in suppressing induction and progression of NBP-
induced breast cell carcinogenesis. Although precise mechanisms still need to be elucidated, it 
was evident that the enhanced antioxidant activity of combined green tea catechins and 
combined ergosterol and mimosine markedly reduced ROS elevation caused by NBP giving the 
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DNA in these cells a level of protection against proliferative and oxidative DNA damage that 
neither agent achieved alone. Based on our results, it appears as though a combination of dietary 
agents is the best course of action to suppress cellular carcinogenesis caused by exposure to 
combined environmental and dietary carcinogens. Therefore, applying our cellular model will 
advance our understanding of novel preventive agents that are effective in reducing the health 
risk of sporadic breast cancer associated with chronic exposure to carcinogens present in 
environmental pollution and American diet. 
 
Conclusion 
 This study has shown that repeated exposure of non-cancerous, human breast epithelial 
MCF10A cells to low doses of the environmental carcinogens NNK and B[α]P enhances various 
cancer-associated properties, including reduced dependence on growth factors, anchorage 
independent growth, enriched stem-like cell population and activation of the EMT program, 
induced by chronic exposure to the dietary carcinogen PhIP. We also detected the ability of 
dietary compounds such as green tea catechins, ergosterol and mimosine, at non-cytotoxic 
concentrations, to suppress progressive carcinogenesis of breast epithelial cells induced by 
chronic exposure to multiple carcinogens. This scheme is summarized in Figure 4.1. 
 To identify the mechanisms involved in NBP-induced chronic breast cell carcinogenesis, 
we characterized biological, biochemical, and molecular changes transiently induced by short-
term carcinogen exposure. Short-term exposure to physiologically-achievable doses of NBP 
induced transient ROS elevation leading to ERK pathway activation, cell proliferation, and 
chromosomal DNA damage (Figure 4.2A). Ras-ERK pathway-mediated induction of the Nox-1 
enzyme facilitated further production of ROS which led to elevated levels of oxidative DNA 
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damage. We observed that a combination of the green tea catechins ECG and EGCG, as well as a 
combination of the fungal sterol ergosterol and the rare plant amino acid mimosine, were more 
effective than individual agents in blocking NBP-induced ROS elevation, ERK pathway 
activation, cell proliferation, DNA damage and DNA oxidation, and ultimately suppressing the 
progression of cellular carcinogenesis (Figure 4.2B). Our work suggests that use of combined 
dietary agents should be seriously considered for early intervention of breast cell carcinogenesis 
associated with long-term exposure to multiple environmental and dietary carcinogens. 
 
Future Directions 
Co-exposure to NB and PhIP enhanced cellular acquisition of all the cancer-associated 
properties we tested; however, whether co-exposure to NB and PhIP may enhance cellular 
tumorigenicity and mammary tumor development in animals, as well as human breast cancer 
development, remains to be determined.  Suppression of cellular acquisition of stem-like cell- 
and EMT-associated properties by green tea catechins, ergosterol and mimosine were indicated 
by reduction in mammosphere formation, decreased ADLH-positive cell populations and 
reversal of EMT marker expression. However, whether or not these dietary agents are able to 
protect mammary tissues from acquiring carcinogen-induced stem-like cell and EMT-associated 
properties to reduce the risk of invasive tumors remains to be studied.  
In our studies, exposure of MCF10A cells to NNK and B[α]P (NB) did not induce any 
detectable upregulation of Ras or phosphorylated-Raf, both of which are upstream from Mek1/2 
and Erk1/2. Thus, it appears that NB-elevated ROS induced the ERK pathway in a Ras/Raf-
independent manner. However, the mechanism for NB-mediated Ras-independent Mek1/2 
phosphylation and ERK pathway activation and how ROS was able to induce Ras/Raf-dependent 
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and -independent activation of Mek1/2 and Erk1/2 remains to be determined. As a major source 
of ROS production, Ras-ERK-dependent expression of Nox-1 plays an important role in redox 
signaling and mediates the interplay that occurs between ROS production and the Ras-ERK 
pathway in NBP-exposed cells. Cellular exposure to NB did not induce significant expression of 
Nox-1 in our studies, presumably because NB did not upregulate Ras expression. However, 




LIST OF REFERENCES 
1. DeBruin LS, Josephy PD (2002) Perspectives on the chemical etiology of breast 
cancer. Environ Health Perspect 110 Suppl 1: 119-128. 
2.   Hecht SS (2002) Tobacco smoke carcinogens and breast cancer. Environ Mol Mutagen 
39: 119-126. Carcinogenesis 21: 345-351. 
3.   Guengerich FP (2000) Metabolism of chemical carcinogens.  
4.   Mehta RG (2000) Experimental basis for the prevention of breast cancer. Eur J Cancer 
36: 1275-1282.  
5.   Cavalieri E, Rogan E, Sinha D (1988) Carcinogenicity of aromatic hydrocarbons directly 
applied to rat mammary gland. J Cancer Res Clin Oncol 114: 3-9.  
6.   Li D, Zhang W, Sahin AA, Hittelman WN (1999) DNA adducts in normal tissue adjacent 
to breast cancer: a review. Cancer Detect Prev 23: 454-462.  
7.   Rundle A, Tang D, Hibshoosh H, Estabrook A, Schnabel F, et al. (2000) The relationship 
between genetic damage from polycyclic aromatic hydrocarbons in breast tissue and 
breast cancer. Carcinogenesis 21: 1281-1289.  
8.   Rubin H (2011) Synergistic mechanisms in carcinogenesis by polycyclic aromatic 
hydrocarbons and by tobacco smoke: a bio-historical perspective with updates. 
Carcinogenesis 22: 1903-1930.  
9.   Pluchino LA, Wang HC (2014) Chronic exposure to combined carcinogens enhances 
breast cell carcinogenesis with mesenchymal and stem-like cell properties. PLOS One 
(Accepted). 
10. Pluchino LA, Liu AK, Wang HC (2014) Reactive oxygen species-mediated enhancement 
of breast cell carcinogenesis by multiple carcinogens intervened by the dietary  
204 
 
      constituents ergosterol and mimosine. Free Radicial Biology and Medicine (Submitted). 
11. Hanahan D, Weinberg RA (2011) The hallmarks of cancer: the next generation. Cell 144: 
646-674. 
12. Ohigashi H, Murakami A (2004) Cancer prevention with food factors: alone and in 
combination. Biofactors 22: 49-55.  
13. Butler LM, Wu AH, Wang R, Koh WP, Yuan JM, et al. (2010) A vegetable-fruit-soy 
dietary pattern protects against breast cancer among postmenopausal Singapore Chinese 
women. Am J Clin Nutr 91: 1013-1019.  
14. Bialy TL, Rothe MJ, Grant-Kels JM (2002) Dietary factors in the prevention and 
treatment of nonmelanoma skin cancer and melanoma. Dermatol Surg 28: 1143-1152.  
15. Murakami A, Takahashi D, Koshimizu K, Ohigashi H (2003) Synergistic suppression of 
superoxide and nitric oxide generation from inflammatory leukocytes by combined food 
factors. Mutat Res 523-524: 151-161. 
16. Hsu A, Bruno RS, Löhr CV, Taylor AW, Dashwood RH, et al. (2011) Dietary soy and tea 
mitigate chronic inflammation and prostate cancer via NFκB pathway in the Noble rat 
model. J Nutr Biochem 22: 502-510.  
17. Zuniga KE, Clinton SK, Erdman JW (2013) The interactions of dietary tomato powder 
and soy germ on prostate carcinogenesis in the TRAMP model. Cancer Prev Res 6: 548-
557.  
18. Bonnesen C, Eggleston IM, Hayes JD (2001) Dietary indoles and isothiocyanates that are 
generated from cruciferous vegetables can both stimulate apoptosis and confer protection 
against DNA damage in human colon cell lines. Cancer Res 61: 6120-6130. 
205 
 
19. Zhou JR, Li L, Pan W (2007) Dietary soy and tea combinations for prevention 
of breast and prostate cancers by targeting metabolic syndrome elements in mice. Am J 
Clin Nutr 86: s882-888.  
20. Meeran SM, Patel SN, Li Y, Shukla S, Tollefsbol TO (2012) Bioactive dietary 
supplements reactivate ER expression in ER-negative breast cancer cells by active 
chromatin modifications. PLoS One 7: e37748.  
21. Hu Y, McIntosh GH, Le Leu RK, Nyskohus LS, Woodman RJ, et al. (2013) 
Combination of selenium and green tea improves the efficacy of chemoprevention in a rat 










Figure 4.1  
Schematic representation of progressive induction of cancer-associated properties by 














(A)  Hypothetical mechanism of NBP-induced cellular carcinogenesis 
(B) Hypothetical mechanism of suppression of NBP-induced cellular carcinogenesis  
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